



The Rosalind and Morris Goodman Cancer Research Centre

Annual Report

January – December 2012

Table of Contents

Section I: Unit Status Update

Highlights of achievements and activities for the year 2012 page 4

Section II: Supporting documentation

Appendix I List of academic staff page 10

Appendix II Grants page 11

Appendix III Salary support page 26

Appendix IV Publications page 27

Appendix V Community involvement page 43

Section III: Confidential Information

Appendix VI Consulting Activities Table page 61

Section I

Unit Status Update

Rosalind and Morris Goodman Cancer Centre Annual Report 2012

I. Introduction

The Rosalind and Morris Goodman Cancer Research Centre (GCRC) is recognized as one of the leading cancer research centers in Canada and abroad. Its thematic division into 5 units: *Breast Cancer, Metabolism and Cancer, Development and Cancer, Stem Cells and Signaling*, and *DNA and Apoptosis*, has resulted in creating a critical mass of specialists who are accelerating discoveries in these fields of research, initiating meaningful partnerships with clinical and basic scientists at a national and international level, and are very effective at securing personal and team grants with external funding agencies. Most importantly, the emphasis is on fundamental, translational and clinical aspects of cancer research, maintenance of the cutting-edge, state-of-the art facilities and enriched, multidisciplinary, and collaborative training environment. As such, the Centre attracts many gifted trainees, research staff, and scientific interest. Despite budgetary limits and national economic constraints the Centre continues to deliver more with less due to its lean policy and close administrative oversight.

The mission of the Goodman Cancer Research Centre has remained the same since its establishment in 1978. The three major elements are as follows:

- 1) To bring together internationally renowned scientists devoted to cancer research and provide them with the best resources available so that they are poised to fully contribute to the worldwide effort to cure cancer.
- 2) To provide an internationally recognized state-of-the-art training platform for the next generation of researchers.
- 3) To promote to the public and to the medical community the importance of fundamental research for the advancement of cancer understanding, prevention, prognosis and treatment.

In 2012, the GCRC had 25 full members, 31 associate members, 57 MSc students, 68 Ph.D. students, 52 postdoctoral fellows, and 14 summer students.

The 2012 achievements and activities are summarized below.

II. Research and Publications

The overall research activities in the Centre are supported by the grants secured and held by the full members of GCRC (Full list of GCRC members: Appendix I). Specifically, in 2012 the total amount of grants held by GCRC and their full members (Grants: Appendix II) amounted to \$ 17 million:

- Infrastructure Grants: \$900,000
- Team Grants (6 grants): \$4,084,170 (24% of total grants held)
- Individual Grants (25 full members; total of 134 grants held): \$11,954,801
 - Individual grants secured in 2012 (17 full members; 35 grants): \$1,706,687 (10% of total grants held)

GCRC continued to hold the prestigious Fonds de recherche du Québec – Santé (FRQS) research group status in 2012 with a direct funding of \$425,000 per year. This funding is in place until year 2015. In addition, financial support from CFI-IOF in the amount \$150,000 was available in support of the newly established Metabolomics Facility (CFI-VI 2009; 2010-2016 total funding period).

The Centre continues to offer a very much sought-after research training environment and manages the McGill Integrated Cancer Research Training Program for which a competitive grant was secured from CIHR/FRQS in the amount of \$325,000 per year (2009-2015 total funding period). Thanks to this initiative, close to 30 trainees per year receive partial salary support while pursuing cancer research at not

Rosalind and Morris Goodman Cancer Centre Annual Report 2012

only GCRC but also at the Segal Cancer Centre and MUHC RI. Similarly, 20 trainees per year benefit from travel support to present their research at national and international scientific meetings.

Research at the Centre continues to be supported by the funding received via 6 Team grants secured by the GCRC researchers, where 2 of the grants were obtained in 2009 (CIHR, CCSRI), 2 in 2010 (GQ, QCDM) and 2 in 2011 (CIHR, GQ). The importance of these team grants lies in the fact that 1) it reflects the strength of the collaborative spirit of the members of the Centre, and 2) portion of the funds are dedicated towards the research and operations of key facilities established at GCRC (Metabolomics Facility, Laboratory for Therapeutic Development, Histology, Transgenic and Functional Genomics Core Facilities).

Individual funding obtained by the full members of the GCRC, is due to the innovative work of our colleagues and the existence of outstanding infrastructure. In 2012, all of our full members held grants (135) in the amount of \$11,954,801 to support their research activities, trainees and personnel. Of those, \$1,706,687 was secured in the form of operating grants by 17 researchers in 2012 (35 grants). Additionally, 16 of GCRC members held salary support from the prestigious career awards totaling over \$ 1 million (Detailed list: Appendix III). We are happy to report that our newest member, Dr. George Zogopoulos who joined the GCRC as a full member in 2011, successfully secured salary support in 2012.

In addition, and among other GCRC exceptional outputs, GCRC PIs have filed several patents and licensing agreements.

- Altering survival dependencies in cells and uses thereof. Mills, J., Malina, A., and Pelletier, J. PCT/US 61,612,426. Filed Jan. 3, 2012
- Inflammation-enabling polypeptides and uses thereof cross-reference to related applications” Gros, P.; US Provisional Patent Application serial No. 61/652,271; Filed May 25th 2012.

Researchers continue to publish actively and in 2012 they collectively published over 137 peer reviewed manuscripts and book chapters, a 33% increase over the previous reporting period. Many of these were published in the leading scientific journals in the world: Nature, Nature Immunology, Nature Communications, Cancer Cell, Molecular Cell, Cell Metabolism, Oncogene, Cancer Research, Molecular Cell Biology, Journal of Immunology, Development, and PNAS among others (Detailed list of publications: Appendix IV).

III. Conferences and Symposia

Each year the GCRC members are involved in the organization of the national and international scientific conferences and/or symposia.

- Dr. Philip Branton and Dr. Jose Teodoro organized the 2012 DNA Tumour Virus meeting for the first time in Montreal (July 16 – 21, 2012). This meeting brings together a diverse group of researchers, from all over the world, with common research interests in the study of the small DNA tumor viruses. It is the first time since 1969 that this meeting was held in Montreal.
- Dr. Nicole Beauchemin was part of the organization committee for the Signalisation-Quebec meeting in Trois-Rivières in 2012. This meeting brings together all researchers in Quebec using Molecular Signaling as readout of their phenotypic experiments.
- Dr. Russell Jones was a co-organizer of the FASEB Summer Research Conference entitled “AMPK and Beyond: Biology, Disease Mechanisms and Therapeutic Opportunities” and held in Asilomar, CA, USA (October 7-12, 2012).
- Dr. Arnim Pause was the member of the scientific committee, session chair, and invited speaker at the

Rosalind and Morris Goodman Cancer Centre Annual Report 2012

The Fourth Birt-Hogg-Dube (BHD) Symposium in Cincinnati, USA (2012).

- Dr. Nahum Sonenberg was the co-organizer with D. Tollervy, J. Steitz and A. Ephrussi of the EMBO/EMBL Symposium 2012 “Complex Life of mRNA” in Heidelberg, Germany (October 7-10, 2012).

Many of GCRC members travel extensively as invited speakers/research experts to present at national/international meetings or at the departmental seminars and workshops. Among more prestigious presentations in 2012 were:

- Dr. N. Beauchemin gave a Keynote address at the 40th annual meeting of International Society for Oncology and Biomarkers (ISOBM), Jerusalem, Israel (October 13-17, 2012).
- Dr. N. Sonenberg gave a keynote address at the workshop entitled “mRNA FATE: Life and Death of mRNA in the Cytoplasm” organized by the RNA Society in Riva del Garda, Italy (May 23-26, 2012).

IV. Teaching and learning

The Centre continues to provide a rich and stimulating training environment. In 2012 all of our scientists taught in various undergraduate/graduate level courses, served as course coordinators or on academic advisory boards, supervised and mentored graduate and postdoctoral trainees. Few highlights include:

Teaching Excellence Award: Dr. Russell Jones received the “*Dr. Ann Wechsler Award for Excellence in the Teaching of Physiology*” in 2012 (also recipient in 2011 and 2013).

Teaching initiatives: The Experimental and Clinical Oncology Course EXMD 635 continues to be administered and managed by GCRC. It is a year-long, trans-disciplinary course with lectures on the latest and most relevant cancer disciplines delivered by 40 basic and clinical researchers, who are experts in their respective fields. Lectures on different types of cancer are given by a team of 2 professors (basic scientist paired with a clinician) such that students learn how the basic research knowledge makes its way into clinical practice and decision-making. Tumor Board meetings are offered as part of the course must be attended by all students. This activity puts in perspective the lessons learned at the bench and their impact on clinical decision-making process in cancer treatment. The course is very popular and the registration for the 2012-2013 academic year was at its record-high of 51 students. In 2012, Dr. Nicole Beauchemin submitted a proposal for initiation of substantial course review which commenced in the Fall of 2012.

We are also very proud of our trainees who continue to apply and receive competitive funding support. In 2012, graduate students and postdoctoral fellows received stipend awards for a combined total of \$373,000 by means of internal funding competitions.

- McGill Integrated Cancer Research Training Program Awards: *Graduate Students:* S. Kaur, T. Griss, D. Papadopoli, A. Smith, L Forest, V Sung, Ch. Tam, A. Kreps, L. Jones, S. Chatterjee, A. Hurikawa, A. Lai; *Postdoctoral fellows:* D. Langlais, R. Pal, E. Audet-Walsh.
- Canderel Awards: *Graduate students:* Ch. Cyr-Depauw, Y. Stern, Z. Andrei; *Postdoctoral fellows:* M. Poffenberger, E Matta Camacho

In addition, numerous GCRC trainees (M.Sc. and Ph.D. students as well as PDFs) also secured funding from external sources, including provincial, federal and international funding agencies (FRQS, CRS, CIHR, Susan Komen, US Army – DOD, and many others). Combined with the internal studentships, GCRC trainees secured just over 1.6 million dollars competitive awards.

V. **Involvement in the community**

The GCRC and its members highly value the involvement in the community. For this reason, the Goodman Public Forum lecture series have been developed with a specific goal of broadcasting scientific discoveries and knowledge to the general public. These events are moderated by Dr. Nicole Beauchemin and are very popular and very well attended (200 participants). In 2012, GCRC have delivered 4 such events:

- October 15, 2012: Bladder and prostate cancer (Invited panelists: Drs. Fred Saad, Michel Tremblay, Wassim Kassouf and cancer survivor).
- November 12, 2012: cancer looking for simplicity and finding complexity (Invited Panelists: Drs. Walter Gotlieb, Anne-Marie Mes-Masson, John Stagg).
- March 13, 2012: Lung Cancer: Myths, facts, choices (Invited Panelists: Drs. Simon Rousseau, Jason Agulnik, Bassam Abdulkarim).
- April 24, 2012: Melanoma: making a mountain out of a mole? (Facilitator: Dr. Nicole Beauchemin; Invited Panelists: Drs Henry Shibata, Beatrice Wang, Francine Tremblay, David Dankort).

In addition, each member of the GCRC dedicates a lot of their time to sit on the scientific and academic committees, to actively participate in the grant, journal and advisory review panels and editorial boards, and is often invited to be part of the McGill's internal committees (please see Appendix V for details).

VI. **Milestones:**

Dr. Morag Park has accepted the position of the GCRC Director in the fall of 2012 and will commence her official mandate on July 1st, 2013.

Promotions:

Associate Professorship:

- Dr. T. Duchaine became the Associate Professor in Department of Biochemistry at McGill University on June 2012.

Associate Members:

- Dr. G. Zogopoulos an Associate Member of the Department of Human Genetics and Medicine (Division Experimental Medicine) at McGill University in 2012.
- Dr. J. Teodoro became the Associate Member of the Department of Microbiology and Immunology at McGill University in April 2012.
- Dr. Lorenzo Ferri, an Assistant Professor in the Departments of Surgery has become GCRC newest member in 2012. His research focus is on 1) the role of systemic inflammation in cancer metastasis, 2) signaling in cancer cells, and 3) neutrophil role in cancer progression.

Retirement:

Dr. Maria Zannis-Hadjopoulos indicated her desire to retire as of June 2013.

Administration:

- Mr Jacques Hendlisz completed his mandate of reorganizing the GCRC administrative infrastructure and left GCRC in December 2012.
- Ms Petra Gaiser was hired as the administrative officer at GCRC starting January 2013. Her mandate includes optimization of the administrative and research operations.

Rosalind and Morris Goodman Cancer Centre Annual Report 2012

New faculty positions:

GCRC has initiated a search to fill two new faculty positions in the area of lung cancer. The first is the Goodman endowed chair in lung cancer, which is targeting an established clinician/scientist that will bridge clinical and basic research in the field of lung cancer. The second is an Assistant Professor position for a basic research scientist interested in the molecular mechanisms driving lung cancer initiation and progression. These searches are currently ongoing with the anticipated recruitment to these positions concluding in 2013/2014.

VII. **Honors, awards, and prizes:**

Some of our faculty members received prestigious recognitions:

- Dr. N. Beauchemin was nominated by the Dept. of Oncology and the Goodman Cancer Research Centre for the Royal Society of Canada. Dossier will go forward next year.
- Dr. T. Duchaine became the Riboclub Alumni of the Year (Distinction with honorary lecture)
- Dr. Jerry Pelletier was awarded James McGill Professor, McGill University (2012-2019)
- Dr. N. Sonenebrg received the Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Science
- Dr. M. Tremblay received the Prix Michel Sarrazin 2012 from Club de Recherche Clinique du Quebec
- Dr. G. Zogopoulos became the Alternate Appointee for the Franklin Martin Faculty Research Fellowship, American College of Surgeons

Finally, some of GCRC members take part in consulting activities (Consulting Activities Table: Appendix VI).

We are incredibly proud of the achievements of our faculty, trainees and staff of the Goodman Cancer Research Centre. Our researchers remain highly competitive in both the excellence of their research programs and their ability to secure funding, at all levels, in an increasingly competitive funding environment. As we look forward to 2013, we welcome Dr. Morag Park as the 7th Director of the Goodman Cancer Research Centre. The arrival of Dr. Park will provide the opportunity for the GCRC to define its strategic priorities moving forward at a time when similar initiatives are being pursued at the Faculty and University levels. We also look forward to launching the recruitment process to develop a critical mass in lung cancer research that will add to and grow our strength in this area. As Universities across Canada struggle with current fiscal realities, we are fortunate that the GCRC can continue to develop new areas of research strength that complement our existing research excellence. Finally, we are fortunate that we enjoy the unwavering support of Rosalind and Morris Goodman, which allows the Centre to strategically develop in these challenging times.

Sincerely,

A handwritten signature in black ink, appearing to read "Peter Siegel". The signature is stylized with large, overlapping loops and a cursive script.

Peter Siegel, Interim Director

Section II

Supporting documentation

APPENDIX I

Unit Status Update

BEAUCHEMIN, Nicole, Professor (on leave Jan - Dec 2012)
BOUCHARD, Maxime, Associate Professor (active)
BRANTON, Philip, Professor (active)
DUCHAINE, Thomas, Associate Professor (active)
GALLOUZI, Imed, Associate Professor (active)
GIGUERE, Vincent, Professor (active)
GROS, Philippe, Professor (active)
HALLETT, Michael, Associate Professor (active)
JONES, Russell, Assistant Professor (active)
McCAFFREY, Luke, Assistant Professor (active)
MULLER, William, Professor (active)
NEPVEU, Alain, Professor (active)
PARK, Morag, Professor (active)
PAUSE, Arnim, Associate Professor (active)
PELLETIER, Jerry, Professor (active)
SHORE, Gordon, Professor (active)
SIEGEL, Peter, Associate Professor, Interim Director at GCRC (active)
SONENBERG, Nahum, Professor (active)
ST-PIERRE, Julie, Assistant Professor (active)
TEODORO, Jose, Assistant Professor (active)
TREMBLAY, Michel, Professor (on leave till October 2012)
YAMANAKA, Yojiro, Assistant Professor (active)
YANG, Xiang-Jiao, Professor (active)
ZANNIS-HADJOPOULOS, Maria, Professor (on leave till June 2012)
ZOGOPOULOS, George, Assistant Professor of Surgery (active)

Funding

APPENDIX II Research Grants Obtained (January-December 2012)

Notes:

Infrastructure Grants – from \$851,250 (2011) to \$900,000 (2012)
 Group Grants – from \$3,441,640 (2011) to \$4,084,170 (2012)
 Individual Grants – from \$11,189,864 (2011) to \$11,954,801 (2012)

Please note that GCRC secured funds for this reporting period are:

- \$900,000 secured from granting agencies for GCRC personnel, training activities (trainees salary support) and establishing and maintenance of Metabolomics Facility
- \$4,084,170 secured for team driven research programs
- \$11,954,801 secured by GCRC full members for their research projects

Dollar amounts indicated are for the actual number of funded months in 2012. i.e. If the funding period spans across only 3 months in 2012, the amount indicated represents 3 months of funding.

*For group grants on which the PI is part of the Goodman Cancer Research Centre (GCRC), the full amount of funding for 2012 (12 months) has been attributed to the PI for reporting purposes. For group grants on which the PI is **not** from the GCRC, the individual researcher's share for the 12-month period is indicated.*

GCRC Infrastructure Grants (total \$900,000)

Agency	Type	Team Leader	Title	Funding Period	Jan-Dec 2012
FRSQ	Infrastructure		Groupe de recherche sur le cancer de McGill	04/2011-03/2015	\$425,000
CIHR/FRSQ	Strategic Training Initiative	Michel Tremblay	The CIHR/FRSQ Training Program in Cancer Research at McGill (Training grant of the GCRC, Segal Cancer Centre and MUHC) (MICTRP) CoPI: Wilson Miller CoApps: Beauchemin, Bouchard, Duchaine, Giguere	04/2011-03/2015	\$325,000

Goodman Cancer Research Centre Annual Report 2012

			+ 40 others (GCRC, McGill and MUHC)		
IOF-CFI_6	Institutional Operating Fund <ul style="list-style-type: none"> • CFI portion • FacMed • Provost 	Vincent Giguere	Metabolism and Cancer: From Obesity to Cachexia	06/2010-06/2016	\$150,000

GCRC Group Grants (total \$4,084,170)

Agency	Type	Team Leader	Title	Funding Period	May2011-Apr2012
CIHR	STIHR	Michael Hallett	Integrative Approaches to Human Health CoApps: Gros, Muller, Park, Pelletier, Siegel + 46 others (GCRC, McGill and MUHC)	04/2009-03/2015	\$298,333
CIHR	TFNFPC	Michel Tremblay	Defining and Applying “Oncometabolism”: A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities. CoPIs: Jones, Pause, Sonenberg, St-Pierre CoApps: Avizonis, Beauchemin, Giguere, Hardy, Nadon, Pollak, Topisirovic	07/2011-06/2014	\$1,277,101
CCSRI	TFFNFPPG	William Muller	Preclinical models and therapeutic targets for metastatic breast disease CoApps: Giguere, Hallett, Muller, Park, Siegel	07/2009-06/2014	\$1,030,684
GQ	Genomics Research in Human Health	Michael Hallett	Next Generation Predictive Signatures for Breast Cancer CoApps: Avard (McGill, Human Genetics), Gaboury (IRIC), Muller, Nepveu, Park, Siegel, Ursini-Siegel (LDI/JGH)	01/2011-12/2013	\$483,186
GQ	Concours santé-volet translationel	Gordon Shore	Plateforme de développement thérapeutique : ciblage métabolique pour le traitement du cancer CoPI: Michel Tremblay CoApps: Giguere, Jones, Pelletier, St-Pierre and J. Lachaine (U de M)	10/2010-09/2013	\$324,869
CQDM	Operating	Gordon Shore	Integrated Platform: Synthetic Lethality in Cancer CoApps: Muller, Pelletier, Sonenberg, Tremblay	09/2010-08/2013	\$669,997

GCRC Individual Grants (total \$11,954,801)

BEAUCHEMIN, Nicole

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		Metabolic functions of the PTPase SHP-1 in insulin target tissues	04/2012-03/2017	\$18,750
CIHR	Operating		CEACAM1 in colon cancer progression and metastasis	04/2012-03/2017	\$125,115
CCSRI	Innovation		Host genetic determinants of colon cancer metastasis	01/2012-12/2014	\$8,333
CRS	Operating	Co-PI wGros	Genetic control of susceptibility to colon cancer development	09/2012-08/2014	\$10,000
CIHR	TFNFPC	wTremblay	Metabolic control pathways in cancer: Control of the Warburg effect by AMPK CoPIs: Jones, Pause, Sonenberg, St-Pierre CoApps: Avizonis, Beauchemin, Giguere, Hardy, Nadon, Pollak, Topisirovic	07/2011-06/2014	see Group Grants
CQDM	CQDM		SN-38 (or 5-FU) drug encapsulation in liposomes transported by magnetotactic bacteria for localized colorectal cancer treatment	09/2011-08/2014	\$11,000
CRS	Operating	Co-PI wGros	Genetic Control of Susceptibility to Colon Cancer	09/2010-08/2012	\$20,000
CIHR	Operating		CEACAM1 in colon cancer progression	04/2008-03/2012	\$46,126
CIHR	Operating		Metabolic functions of the PTPase SHP-1 in insulin target tissues	04/2007-03/2012	\$4,250

BOUCHARD, Maxime

Agency	Type	Grant #	Title	Funding Period	Amount 2012
KFoC	Biomedical Research Grant		Mouse models of urogenital developmental diseases	07/2012-06/2014	\$25,000
McGill U.	Fac of Med Bridge Funding		Specification and Morphogenesis of the Urogenital System Primordium	10/2012-09/2013	\$8,750
CRS	Operating		Gata3 and the Androgen Receptor Response in Prostate Cancer	09/2011-08/2013	\$60,000
CIHR	Operating		Transcriptional network of urogenital system development in the mouse	09/2007-08/2012	\$86,904
CIHR	Operating		LAR-family receptor tyrosine phosphatases in urogenital system malformations	09/2007-08/2012	\$83,199

Goodman Cancer Research Centre Annual Report 2012

KFC	Biomedical Research Grant		Mouse models of urogenital system developmental diseases	07/2010-06/2012	\$25,000
-----	---------------------------	--	--	-----------------	----------

BRANTON, Philip

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		Role of the E4orf6/E1B55K E3 ubiquitin ligase in the adenovirus life cycle	04/2010-03/2015	\$221,455
CIHR	Operating		Mechanism of action of the adenovirus death protein E4orf4 (total \$145,894/yr less Teodoro's \$20,000/yr)	04/2009-03/2014	\$125,894
CIHR	Dissemination Events		Montreal DNA Tumour Virus Meeting 2012	2012	\$16,756

DUCHAIINE, Thomas

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		Synergistic miRNA-binding sites, and 3' untranslated regions: a dialogue of silence	10/2012-09/2017	\$33,170
NSERC	Discovery Grants		Making sense of antisense: the activities of RNA-dependent RNA polymerases in endogenous RNAi	04/2012-03/2017	\$21,127
CIHR	Operating	wSonenberg	Mechanism of microRNA action in translation and mRNA decay	04/2009-03/2014	
CIHR	Operating		RNAi-mediated Genetic Regulation Loops	03/2008-03/2013	\$125,323
CFI	Leaders Opportunity Fund		An integrative approach on small RNA-mediated silencing in Canada	09/2007-09/2012	\$60,644
NSERC	Discovery Grant		The role of tandem tudor domain proteins in RNAi	04/2007-03/2012	\$7,043

GALLOUZI, Imed

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		The role of trans- and cis-acting factors in the regulation of mRNA encoding modulators of senescence and SASPs	04/2012-03/2017	\$120,591
CIHR	Operating		The RNA binding protein HuR is a key player in muscle cell differentiation	09/2008-09/2013	\$135,184
NSERC	Discovery Grant		Identification of the posttranscriptional regulatory network of the pro-inflammatory cytokine HMGB1	07/2009-06/2014	\$56,000

Goodman Cancer Research Centre Annual Report 2012

NCIC	Operating		The RNA binding protein HuR is a key player in cancer induced muscle wasting	07/2007-06/2012	\$64,000
------	-----------	--	--	-----------------	----------

GIGUERE, Vincent

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		Molecular and genetic analysis of ERR function in breast cancer	10/2011-09/2016	\$165,216
CIHR	Operating		Transcriptional control of metabolism by estrogen related receptors (ERRs)	04/2011-03/2016	\$172,628
GQ	Large-scale project	wShore	Therapeutic development platform: targeting metabolism in cancer therapy	07/2011-06/2014	see Group Grants
CIHR	TFNFPC	wTremblay	Defining and Applying Oncometabolism	07/2011-06/2014	see Group Grants
CCSRI	TFFNFPPG	wMuller	Preclinical models and therapeutic targets for metastatic breast disease	07/2009-06/2014	see Group Grants
Omega-Chem Inc.	Research Contract		Biological Testing of DIAT-Steroids on a series of Nuclear Receptors	02/2012-06/2012	\$15,193
GQ	Pilot Project	wSt-Pierre	Metabolomics of ErbB2-induced breast tumors	10/2010-09/2012	
CIHR	Operating		Genetic and functional analyses of orphan nuclear receptor functions	10/2007-09/2012	\$145,674

GROS, Philippe

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		Genetic studies of blood stage malaria: from mouse models to human disease	04/2012-03/2017	\$106,675
CIHR	Operating		Role of Vangl proteins in normal development and in neural tube defects	10/2011-09/2016	\$146,148
NIH (USA)	Investigator Initiated Research		Genetic determinants of susceptibility to mycobacterial infections	04/2011-12/2015	\$177,310
CRS	Operating	Co-PI wBeauchemin	Genetic control of susceptibility to colon cancer development	09/2012-08/2014	\$10,000
CIHR	Team Grant	wVidal	CIHR Team in ENU mutagenesis and infectious diseases	09/2008-08/2013	\$150,000
GCRC, GQ and McGill U Innovation Centre			Genomic analysis of the host: microbiota interface in the development of colitis and colorectal cancer	2012-2013	\$10,000

Goodman Cancer Research Centre Annual Report 2012

CRS	Operating	Co-PI wBeauchemin	Genetic control of susceptibility to colon cancer development	09/2010-08/2012	\$20,000
-----	-----------	----------------------	---	-----------------	----------

HALLETT, Michael

Agency	Type	Grant #	Title	Funding Period	Amount 2012
NIH (USA)	PPG	wOstrowski	Genetic Analysis of the Breast Tumour Microenvironment	04/2012-03/2017	\$33,750
NSERC	Discovery		Signature Analysis Tools for the Life Sciences	04/2011-03/2016	\$40,000
CIHR	STIHR		Integrative Approaches to Human Health	04/2009-03/2015	see Group Grants
CQDM		wPark	Development of integrated tumor-microenvironmental classifiers for personalized therapy targeting	09/2011-08/2014	
QBCF/CRS	Strategic Grant	wPark	Development of prognostic predictors integrating tumor-intrinsic and microenvironmental information and translation into clinical tests for ER-negative breast cancer	01/2012-12/2014	
CCSRI	TFFNFPPG	wMuller	Preclinical models and therapeutic targets for metastatic breast disease	04/2009-03/2014	see Group Grants
GQ	Genomics Research in Human Health		Next Generation Predictive Signatures for Breast Cancer	01/2011-12/2013	see Group Grants
FRSQ	Pfizer fonds d'innovation	wPark	Tests pronostiques pour le cancer du sein basés sur l'immunohistochimie intégrant les composantes épithéliales et stromales	07/2010-07/2013	
CCSRI	CBCRA Predictive Oncology Grant	wPark	Development of breast cancer prognostic and predictive markers integrating stromal and epithelial processes and serum markers in triple-negative disease	04/2011-03/2013	
CIHR	Team Grant	wSzyf	Whole epigenome profiling of epigenetic marks of maternal depression and its impact on the offspring epigenome	04/2010-03/2013	\$21,000
GQ	International Collaborations Program in Genomics	wBergeron	Proteomics of the Human Liver in Health and Disease	10/2011-09/2012	\$12,750
GQ		wKimmins	Determining the role of the paternal epigenome in offspring health	08/2010-08/2012	\$9,917
FRSQ	Q-CROC	wBatist	Identification et validation de biomarqueurs de résistance thérapeutique dans le cancer colorectal métastatique	04/2009-03/2012	\$4,250

Goodman Cancer Research Centre Annual Report 2012

CIHR	POP	wNepveu	Validation of the CUX1 Expression Signature as an RT-PCR-Based Prognostic Tool	04/2011-03/2012	
CIHR	Catalyst		Bioinformatics Approaches to cancer research	09/2009-08/2012	\$22,000
NSERC	CHRP	wThomas	Chemical correctors of deltaF508 CFTR trafficking	04/2009-03/2012	\$11,250

JONES, Russell

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	TFNFPC	wTremblay	Defining and applying Oncometabolism	07/2011-06/2014	see Group Grants
CIHR	Catalyst Grant		Development of novel animal models to study the impact of metabolism on aging: Investigating the role of the AMP-activated protein kinase (AMPK)	04/2011-03/2012	\$12,381
GQ	Large-scale project	wShore	Therapeutic development platform: targeting metabolism in cancer therapy	07/2011-06/2014	see Group Grants
CCSRI	Operating		Metabolic control points in lymphomagenesis	07/2010-06/2013	\$137,759
Arthritis Society of Canada	Operating		Metabolic control of CD4+ T cell fate	10/2011-09/2014	\$120,000
CIHR	Operating		Role of the AMP-activated protein kinase (AMPK) in stress resistance and cancer	04/2009-03/2013	\$133,433
CFI	Leaders Opportunity Fund		Metabolism and Cancer: Studying the integration of metabolism and signal transduction in tumourigenesis	09/2009-08/2014	\$32,000

McCAFFREY, Luke

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		Cell polarity in mammary morphogenesis and cancer	04/2012-03/2017	\$110,138
TFF	New Investigator Award		Epithelial polarity in tumor invasion and metastasis	10/2011-09/2014	\$146,371
Cure Foundation	Innovative Research Award		A role for PKC in stem cell renewal in Claudin-low breast cancer	01/2012-12/2012	\$10,000
CFI	Leaders Opportunity Fund		Epithelial polarity in morphogenesis and cancer	01/2012-12/2012	\$240,833
McGill	Start-up Funds		Epithelial polarity in mammary gland development and cancer	08/2010-07/2012	\$55,416

Goodman Cancer Research Centre Annual Report 2012

MULLER, William

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		The role of ErbB2-14-3-3 sigma signaling axis in cancer and development	10/2010-09/2015	\$155,694
NIH (USA)	Program Project		Growth Factor Receptor in Breast Cancer Progression and Metabolic Regulation	09/2010-08/2015	\$191,580
CRS-QBCF	Strategic Grant		Integrin-mediated signal transduction in transgenic mouse models of human breast cancer	01/2012-12/2014	\$149,987
NIH (USA)	Program Project		Mechanisms of breast cancer progression	09/2009-08/2014	\$112,594
CCSRI	TFFNFPPG		Preclinical models and therapeutic targets for metastatic breast disease	07/2009-06/2014	see Group Grants
CIHR	Operating		The role of Epidermal Growth Factor Receptor Family in mammary tumorigenesis and metastasis	04/2009-03/2014	\$155,053
GQ	Research Grant	wHallett	Next Generation Predictive Signatures for Breast Cancer	01/2011-12/2013	see Group Grants
CIHR	Operating		The role of PI3K coupled signaling pathways in mammary tumorigenesis	08/2008-09/2013	\$128,630
CBCRA	Research Grant		The role of ShcA and c-Src signaling pathways in ErbB-2 mammary tumor progression	07/2008-06/2013	\$148,894
CIHR	Bridge Funding		Integrin-mediated signal transduction in mammary tumorigenesis and metastasis	10/2011-09/2012	\$75,000
CRS	Operating		Role of Akt family signaling in ErbB2 mammary tumour progression	09/2010-08/2012	\$40,000

NEPVEU, Alain

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		Transcription and Translesion Synthesis	09/2009-08/2014	\$139,935
NCIC	Operating	014288	Function and Modulation of CUX1 in Cell Cycle Progression	07/2008-06/2013	\$136,448
CBCRA	Operating	014348	CUX1 in Mammary Tumors	07/2008-06/2013	\$149,953
CIHR	Team Grant	CTP-79857	CIHR Team in Cancer Progression and Metastasis	04/2006-03/2011	\$39,987

PARK, Morag

Agency	Type	Grant #	Title	Funding Period	Amount 2012
--------	------	---------	-------	----------------	-------------

Goodman Cancer Research Centre Annual Report 2012

NIH (USA)	PPG	wOstrowski	Genetic analysis of the Breast Tumor Microenvironment	06/2012-05/2017	\$111,606
CIHR	Operating		Role of Gab Family Signal Amplifiers in Tumorigenesis and Invasion	10/2010-09/2015	\$154,481
QBCF/CRS	Strategic Grant		Development of prognostic predictors integrating tumor-intrinsic and microenvironmental information and translation into clinical tests for ER-negative breast cancer	01/2012-12/2014	\$150,000
CQDM			Development of integrated tumor-microenvironmental classifiers for personalized therapy targeting	09/2011-08/2014	\$433,333
CIHR	SDRPS		Role of Crk Adapter Proteins in Cell Invasion and Metastasis	08/2008-07/2014	\$150,000
CCSRI	TFFNFPPG	wMuller	Preclinical models and therapeutic targets for metastatic breast disease	07/2009-06/2014	see Group Grants
CIHR	Operating		Mechanisms of oncogenic activation of the met RTK in human cancer	10/2010-09/2013	\$185,345
GQ	Research Grant	wHallett	Next Generation Predictive Signatures for Breast Cancer	01/2011-12/2013	see Group Grants
FRSQ	Operating		Tests pronostiques pour le cancer du sein basés sur l'immunohistochimie intégrant les composantes épithéliales et stromales	07/2010-06/2013	\$161,350
CIHR	CIHR Training Grant	wHallett	Integrative Approaches to Human Health	07/2010-06/2013	see Group Grants
CCSRI	CBCRA Predictive Oncology Grant		Development of breast cancer prognostic and predictive markers integrating stromal and epithelial processes and serum markers in triple-negative disease	04/2011-03/2013	\$213,313
FRSQ	Network Grant		Banque de tumeurs	04/2007-03/2012	\$12,500

PAUSE, Arnim

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	TFNFPC	wTremblay	Characterization of a novel pathway involved in energy/nutrient sensing	07/2011-06/2014	see Group Grants
CRS	Operating		Metabolic role of the tumor suppressor HD-PTP in lung tumorigenesis	09/2011-08/2013	\$60,000
Myrovlytis Trust, UK	Operating		Functional Characterization of the Folliculin Tumor Suppressor Protein	07/2011-06/2013	\$155,000

Goodman Cancer Research Centre Annual Report 2012

CCSRI	Operating		Role of the inactive tyrosine phosphatase HD-PTP in cancer	07/2010-07/2013	\$138,000
CIHR	Operating		Investigating the mechanism of action of the von Hippel-Lindau tumor suppressor protein	09/2007-08/2012	\$95,867
KFoC	Operating		Functional characterization of BHD, a novel tumour suppressor gene involved in kidney cancer	07/2010-06/2012	\$25,000

PELLETIER, Jerry

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		RNA Helicases in Tumorigenesis	04/2011-03/2016	\$162,253
NIH (USA)	Operating		Targeting the DHX9 Helicase for Small Molecule Probe Discovery	08/2012-07/2015	\$65,013
CIHR	Operating		Modelling Translation Initiation as Cancer Therapy	10/2010-09/2015	\$159,410
CCSRI	Innovation Grant		DHX9 – Evaluating a Novel Anti-Neoplastic Drug Target in Vivo	07/2012-06/2014	\$50,000
CCSRI	Operating		Chemical Dissection of Translation Initiation	07/2009-06/2014	\$138,000
GQ	Large-scale project	wShore	Therapeutic development platform: targeting metabolism in cancer therapy	07/2011-06/2014	see Group Grants
CQDM	Operating	wShore	Integrated Platform: Synthetic Lethality in Cancer Therapy	07/2010-07/2013	see Group Grants
CIHR	POP		Chemotherapeutic Agents for Inhibiting Protein Synthesis	09/2011-08/2012	\$53,333

SHORE, Gordon

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		Bcl-2 family Proteins, Cell Death and the Endoplasmic Reticulum	10/2010-09/2015	\$261,747
GQ	Operating		Therapeutic Development Platform: Targeting Metabolism in Cancer Therapy	10/2010-09/2013	see Group Grants
CQDM	Operating		Integrated Platform: Synthetic Lethality in Cancer	09/2010-08/2013	see Group Grants

SIEGEL, Peter

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		GPNMB as an emerging therapeutic target in metastatic breast cancer	04/2012-03/2017	\$110,680

Goodman Cancer Research Centre Annual Report 2012

CCSRI	Innovation Grant	wSaleh	Host genetic determinants of colon cancer metastasis	02/2012-01/2014	\$0
CCSRI	Research Grant		ShcA-dependent mechanisms driving breast cancer migration and invasion	07/2011-06/2014	\$149,840
CCSRI	TFFNFPPG	wMuller	Preclinical models and therapeutic targets for metastatic breast disease	07/2009-06/2014	see Group Grants
GQ	Research Grant	wHallett	Next Generation Predictive Signatures for Breast Cancer	01/2011-12/2013	see Group Grants
AICR	Research Grant		ErbB2/TGFbeta signaling pathway interactions in breast cancer	01/2011-12/2013	\$94,480
CRS	Operating		Defining Mechanisms by which CCN3 Promotes the Formation of Osteolytic Bone Metastases	09/2011-08/2013	\$60,000

SONENBERG, Nahum

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		eIF4E phosphorylation and breast cancer: regulating tumour-host interactions and metastasis	10/2012-09/2017	\$41,144
CIHR	Operating	114994	The role of mTOR pathway in translational regulation of synaptic plasticity, memory formation and disease	10/2011-09/2016	\$199,637
CIHR	TFNFPC	wTremblay	Defining and Applying “Oncometabolism”: A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities	07/2011-06/2014	see Group Grants
CIHR	Operating		Mechanism of miRNA action in translation and mRNA decay	04/2009-03/2014	\$156,927
CIHR	Operating	MHR-100848	Michael Smith Prize in Health Research	04/2009-03/2014	\$100,000
CRS	Operating		mTOR inhibition and translation control of pancreatic neuroendocrine tumours	09/2011-08/2013	\$60,000
CQDM	Operating	wShore	Integrated Platform: Synthetic Lethality in Cancer	09/2010-08/2013	see Group Grants
CCSRI	Operating		Translational control in oncogenesis: Signaling to the translation initiation factor	07/2010-06/2013	\$142,500
Autism Speaks	Operating		Regulation of neuronal translation in Autism Spectrum Disorders	02/2011-01/2013	\$40,000
CIHR	Operating	MOP-7214	Mechanisms of translation initiation and control in	10/2007-09/2012	\$179,935

Goodman Cancer Research Centre Annual Report 2012

			eukaryotes		
CIHR	Team Grant	HET-85519 wCohen	CIHR Team 'HIV Pathogenesis'	10/2007-09/2012	\$90,337
NIH (USA)	Operating	2R01GM066157- 05A2	Translational control by poly(A)-binding protein and its modulators (Paips)	07/2008-06/2012	\$105,037
NCIC	TFFNFPPG	wBell	Canadian Oncolytic Virus Consortium	07/2007-06/2012	\$94,008
CIHR	Catalyst Grant	IAB112229	The role of mTOR pathway in age-associated memory decline	04/2011-03/2012	\$12,500
MDEIE	Programme de soutien à la recherche		Studying the mechanism of DAP5/p97 action in controlling cap-independent translation in eukaryotic cells	07/2009-06/2012	\$25,000

ST-PIERRE, Julie

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		The role of the PGC-1 transcriptional coactivators in the regulation of breast cancer metabolism	10/2010-09/2015	\$131,088
CIHR	TFNFPC	wTremblay	Defining and Applying "Oncometabolism": A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities	07/2011-06/2014	see Group Grants
GQ	Concours santé-volet translationel	wShore	Plateforme de développement thérapeutique : ciblage métabolique pour le traitement du cancer	09/2010-08/2013	see Group Grants
FRSQ	Fond d'établissement		The role of PGC-1 alpha in the regulation of cancer metabolism	07/2010-06/2013	\$15,000
MCC	McGill-Weizmann partnership		Metabolism and DNA damage response	04/2011-03/2013	\$80,000
GQ	Pilot project		Metabolomics of ErbB2-induced breast tumors	10/2010-09/2012	\$75,000

TEODORO, Jose

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CRS	Operating		Assessment of PTEN-regulated Secreted Factors as Prostate Cancer Biomarkers	10/2012-09/2014	\$15,000
CIHR	Operating		Tumour suppressor mediated mechanisms of angiogenesis inhibition	10/2011-09/2014	\$127,510

Goodman Cancer Research Centre Annual Report 2012

CIHR	Operating	wBranton	Mechanism of Action of the Adenovirus Death Protein E4orf4 (JT share = \$20,000/yr)	04/2009-03/2014	\$20,000
NSERC	Discovery Grant		Biology of Circoviruses	04/2009-03/2014	\$40,000
Lamarre Townshend	Innovation Grant		Targeted Gold Nanoparticles for synergistic melanoma therapy	12/2012-11/2013	\$1,666
CIHR	Dissemination events	wBranton	Montreal DNA Tumour Virus Meeting 2012	02/2012-01/2013	
CIHR/NSERC	CHRP		Self Illuminating Nanoparticles for Melanoma Therapy	04/2010-03/2013	\$42,000
CIHR	Operating		Role of the Anaphase Promoting Complex in Cancer and Viral Infection	04/2008-03/2013	\$116,478
Colon Cancer Canada	Operating		Role of the GOS2 Gene in progression of colorectal cancer	12/2011-11/2012	\$45,833

TREMBLAY, Michel

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Operating		PTP-1b as a target in human cancer	04/2011-03/2016	\$151,989
CCSRI	Operating		Understanding and targeting TC-PTP in immune diseases and cancer	07/2011-06/2014	\$112,089
CIHR	TFNFPC		Defining and Applying “Oncometabolism”: A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities	07/2011-06/2014	See Group Grants
QBCF/CBCRA	Operating		Role of the protein tyrosine phosphatase PRL-2 in breast cancer development and metastasis	01/2009-06/2014	\$131,669
GQ	Large-scale projects	wShore	Plateforme de développement thérapeutique : ciblage métabolique pour le traitement du cancer	10/2010-09/2013	see Group Grants
CRS	CRS/Rob Lutterman Pancreatic Cancer Research Program		Linking cancer anorexia-cachexia syndrome, resting energy expenditure and chronic inflammation state in patients with pancreatic cancer through cellular metabolic mechanisms and their unique metastatic control	07/2010-06/2013	\$99,912
DOD	CDMRP		Characterization of the oncogenic potential of protein tyrosine phosphatase 1B in prostate cancer	03/2009-02/2012	\$25,532

YAMANAKA, Yojiro

Agency	Type	Grant #	Title	Funding Period	Amount 2012
--------	------	---------	-------	----------------	-------------

Goodman Cancer Research Centre Annual Report 2012

NSERC	Discovery Grant		Investigating the transition from head to trunk formation in vertebrate development	09/2012-08/2017	\$18,153
CIHR	Operating		Cell polarity and generation of the first distinct lineages in the mouse embryo	04/2011-03/2016	\$148,909

YANG, Xiang-Jiao

Agency	Type	Grant #	Title	Funding Period	Amount 2012
NSERC	Discovery Grant		Role of the sumoylation machinery in generating induced pluripotent stem cells	04/2012-03/2017	\$25,500
CIHR	Operating		Role of a kinase-deacetylase-MEF2 signaling axis in normal and oncogenic cellular programs	10/2009-09/2014	\$135,477
MDEIE	International Collaboration		Function and regulation of TAZ and YAP, two signal-responsive oncogene products	01/2010-12/2012	\$50,000
CIHR	CIHR-China Collaboration Initiative		Role of epigenetic regulators in mediating anti-aging effects of PTHrP	01/2010-12/2012	\$50,000
NCIC	Operating		Functional analysis of MOZ and MORF histone acetyltransferase complexes	07/2007-06/2012	\$68,126
NSERC	Discovery Grant		Roles of a recurrent phospho-sumoyl switch in coordinated transcriptional control	04/2007-03/2012	\$7,500

ZANNIS-HADJOPOULOS, Maria

Agency	Type	Grant #	Title	Funding Period	Amount 2012
NSERC	Operating		Functional synergy between the DNA topology and DNA repair machineries during the initiation of DNA replication	07/2011-06/2016	\$30,000
CRS	Operating		The role of Ku in breast tumorigenesis: Implications for therapy	09/2010-08/2012	\$40,000

ZOGOPOULOS, George

Agency	Type	Grant #	Title	Funding Period	Amount 2012
CIHR	Research Grant		The Genetics of Hereditary Upper Gastrointestinal Cancers: Beyond CDH1 Germline Mutations	09/2012-08/2017	\$7,333
FRSQ	Establishment of Young		Changements génétiques et épigénétiques des cellules germinales, tumorales et du stroma dans les adénomes	07/2012-06/2015	\$5,000

Goodman Cancer Research Centre Annual Report 2012

	Researchers		pancréatiques		
MUHC RI	NI Start-up Operating		Start-up Operating Funds	08/2011-08/2014	\$75,000
GCRC	NI Start-up Operating		Start-up Operating Funds	08/2011-08/2014	\$10,000
MUHC	MGH Foundation/ Canadian Surgical Research Fund		Genetic Susceptibility to Pancreas Cancer in Quebec	09/2012-08/2013	\$10,000
GCRC/McGill Innovation Centre	Collaborative Project		Characterization of Germline Changes in Pancreatic Adenocarcinoma	10/2012-12/2012	\$30,000

APPENDIX IV

Publications (Jan-Dec 2012) – Total Number of Publications: 137
(including book chapters and reviews)
High Impact Papers – Yellow Highlight

BEAUCHEMIN, Nicole, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Beauchemin%20N.%20%5bAuthor%5d%20McGill>

Host-Related Carcinoembryonic Antigen Cell Adhesion Molecule 1 Promotes Metastasis of Colorectal Cancer. A. Arabzadeh*, C. Chan*, A.L. Nouvion*, S. Benlolo*, L. DeMarte*, C. Turbide*, P. Brodt, L. Ferri and **N. Beauchemin**. In press in *Oncogene* doi: 10.1038/onc.2012.112. (2012).

Hepatocyte-specific SHP-1 disruption uncouples liver insulin resistance from hepatic steatosis and inflammation in diet-induced obesity. E. Xu*, A. Charbonneau, Y. Rolland, K. Bellmann, K. Siminovitch, B.G. Neel, **N. Beauchemin** and A. Marette. *Diabetes* 61(8):1949-58 (2012).

The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction. L. Chen, Z. Chen, K. Baker, E. M. Halvorsen, M. B. Flak, G. Gerber, Y.-H. Huang, J. C. Arthur, K. J. Dery, T. Nagaishi, **N. Beauchemin**, K. V. Holmes, J. E. Shively, C. Jobin, A. B. Onderdonk, L. Bry, D. E. Higgins, R. S. Blumberg. *Immunity*: 37(5):930-46 (2012).

Stromal CEACAM1 expression regulates colorectal cancer metastasis. A. Arabzadeh and **N. Beauchemin**. *OncoImmunol.* 1(7):1205-1207 (2012).

BOUCHARD, Maxime, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bouchard%20M%22%5bAuthor%5d%20McGill>

Grouls S, Iglesias DM, Wentzensen N, Moeller MJ, **Bouchard M**, Kemler R, Goodyer P, Niggli F, Gröne HJ, Kriz W, Koesters R. (2012) Lineage Specification of Parietal Epithelial Cells Requires {beta}-Catenin/Wnt Signaling. *J Am Soc Nephrol.* Jan;23(1):63-72. (Impact factor: 7.1)

Grote, D.*, Marcotte, M.*, and **Bouchard, M.** (2012) Live Imaging of the Developing Mouse Mesonephros. *Methods in Molecular Biology (In press)*. (Book chapter) * Equal contributors.

Fielhaber, J.A., Carroll, S.F., Dydensborg, A.B., Shourian, M., Triantafillopoulos, A., Harel, S., Hussain, S.N., **Bouchard, M.**, Qureshi, S.T., Kristof, A.S. (2012) Inhibition of Mammalian Target of Rapamycin Augments Lipopolysaccharide-induced Lung Injury and Apoptosis. *J. Immunology* 188(9):4535-42.

BRANTON, Philip, Dr.

URL: <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=branton+pe%5BAuthor%5D%22>

Goodman Cancer Research Centre Annual Report 2012

WIMMER, P., P. Blanchette, S. Schreiner, W. Ching, P. Groitl, J. Berscheminski, **P.E. Branton**, H. Will and T. Dobner. 2012. Cross-talk Between Phosphorylation and SUMOylation Regulates Transforming Activities of an Adenoviral Oncoprotein. *Oncogene* 1038, 187 (on-line).

BOROZAN, I., S. Wilson, P. Blanchette, P. Laflamme, S.N. Watt, P.M. Krzyzanowski, F. Sircoulombe, R. Rottapel, **P.E. Branton** and V. Ferretti. 2012. CaPSID: A bioinformatics platform for computational pathogen sequence identification in human genomes and transcriptomes. *BMC Bioinformatics* (on-line 13, 206).

DUCHAINE, Thomas, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Duchaine%20T%20%5bAuthor%5d>

Caroline Thivierge*, Neetha Makil*, Mathieu Flamand, James Wohlschlegel, Jessica J. Vasale, Craig C. Mello, Darryl Conte Jr. and **Thomas F. Duchaine** (Corresponding Author). Tudor domain ERI-5 tethers an RNA-dependent RNA polymerase to DCR-1 to potentiate endoRNAi. *Nat Struct Mol Biol.* 19(1):90-7 (2012). (Published online 18 Dec 2011)

Reviews:

Flamand M, **Thomas F. Duchaine**. SnapShot: endogenous RNAi machinery and mechanisms. (Review) *Cell.* 2012 Aug 3;150(3):662-662.

Flamand M **Thomas F. Duchaine**. SnapShot: endogenous RNAi pathways. (Review) *Cell.* 2012 Jul 20;150(2):442-442.

Sawh AN, **Thomas F. Duchaine**. Turning Dicer on its head. (Review) *Nat Struct Mol Biol.* 2012 Apr 4;19(4):365-6.

GALLOUZI, Imed, Dr.

URL: <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=gallouzi+i%5BAuthor%5D>

Isabelle, M., Gagné, J.P., **Gallouzi, I.E.**, and Poirier, G.G. “Quantitative proteomics and dynamic imaging reveal that G3BP-mediated stress granule assembly is poly(ADP-ribose)-dependent.” *Journal of Cell Science*, Oct 1;125(Pt 19):4555-66, (2012) (Funded by NCIC operating grant # 018125)

Di Marco, S., Cammas, A., Lian, X., Kovacs, E., Hall, D.H., Ma, J., Mazroui, R., Pelletier, J., **Gallouzi, I.E.** “Pateamine A, a natural inhibitor of general translation, prevents the onset of cachexia-induced muscle wasting.” *Nat Commun.* Jun 12;3:896. doi: 10.1038/ncomms1899 (2012). (Funded by NCIC operating grant # 018125)

- This publication identifies Pateamine A as a potential therapeutic option to combat cancer-induced muscle wasting. Based on the promising nature of our findings, the manuscript has been the subject of major news coverage (see below). It was also highlighted by the Canadian Cancer Society as one of the top 10 research achievements of 2012. Website : <http://www.cancer.ca/Canada-wide/About%20us/Media%20centre/CW-Media%20releases/CW-2012/Top%2010%20Society-funded%20research%20of%202012.aspx>

Robert, F., Mills, J., Agenor, A., Wang, D., Di Marco, S., Cecnic, R., Tremblay, ML., **Gallouzi, I.E.**,

Goodman Cancer Research Centre Annual Report 2012

Hekimi, S., Wing, S., and Pelletier, J. "Targeting Protein Synthesis in a Myc/mTOR-driven model of Anorexia-Cachexia Syndrome Delays its Onset and Prolongs Survival." *Cancer Research*, Feb 1;72(3):747-56, (2012) (Funded by NCIC operating grant # 018125)

Peer Reviewed Invited Reviews:

Ma, J.F., Hall, D.T., and **Gallouzi, I.E.** "The impact of RNA turnover and translation on age-related diseases." *Ageing Res Rev.* Epub ahead of print. (2012).

Isabelle, M., **Gallouzi, I.E** and Poirier, G., "PARP1-PARylation promotes silent locus transmission in the nucleolus: the suspicion confirmed." *Preview, Molecular Cell*, 45(6):706-7. (2012)

Book chapter:

Von Roretz, C., **Gallouzi, I.E.** "RNA regulation in apoptosis." Chapter in the book titled "Encyclopedia of Molecular Cell Biology and Molecular Medicine." Edited by Dr Bob Meyers. (2012).

GIGUERE, Vincent, Dr.

URL: [http://www.ncbi.nlm.nih.gov/pubmed?term=%22Giguere%20V%22\[Author\]%20McGill](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Giguere%20V%22[Author]%20McGill)

Deblois, G. and **Giguère, V.** (2012) *News & Views*. Cancer: reprogramming clinical outcome. *Nature* 481: 275-276. PMID: 22258604

Lessard, L., Labbé, D.P., Deblois, G., Bégin, L.R., Hardy, S., Mes-Masson, A.M., Saad, F., Trotman, L., **Giguère, V.** and Tremblay, M.L. (2012) PTP1B is an androgen receptor-regulated phosphatase that promotes the development and progression prostate cancer. *Cancer Research* 72:1529-1537. PMID: 22282656

Deblois, G., St-Pierre, J. and **Giguère, V.** (2012) The PGC-1/ERR axis in cancer. *Oncogene* doi:10.1038/onc.2012.529. PMID: 23208510

GROS, Philippe, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gros%20P%22%20%5bAuthor%5d%20McGill>

Berghout, J., Higgins, S., Lacoubar, C., Sakuntabhai, A., Kain, K. and **Gros, P.** "Genetic diversity in human erythrocytic pyruvate kinase (PKLR)" *Genes Immun.* 13: 98-102, 2012. PMID: 21833022

Laroque, A., Min-Oo, G., Tam, M., Stevenson, MM. and **Gros, P.** "Genetic control of susceptibility to blood stage malaria in inbred mouse strains: Effect of the *Char1* locus" *Genes Immun.* 13: 155-163, 2012. PMID: 21975430

Bongfen, SE, Rodrigue-Gervais, I-G, Berghout, J., Torre, S., Sladek, R., Cingolani, P., Wiltshire, SA., Gabriel A. Leiva-Torres, GA., Sladek, R., Blanchette, M., Lathrop, M., Behr, MA., Gruenheid, S., Vidal, S., Saleh, M. and **Gros, P.** "An N-Ethyl-N-Nitrosourea (ENU)-Induced Dominant Negative Mutation in the Jak3 Kinase Protects Against Cerebral Malaria" *PLoS ONE*, 7(2): e31012, 2012. PMID: 22363534

Torban, E., Iliescu, A. and **Gros, P.** "An expanding role of VANGL proteins in embryonic development", *Curr. Topics Dev. Biol.* 101: 237-256, 2012. PMID: 23140632

Idaghour, Y., Quinlan, J., Goulet, J-P., Gheba, E., Berghout, J., Bruat, V., de Maillard, T., Grenier, J. C., Gomez, S., **Gros, P.**, Rahimy, C.M., Sanni, A., and Awadalla, P. "The genomic architecture of host whole blood transcriptional response to malaria infection", *Proc. Natl. Acad. Sci. USA.* 2012 Sep 4. [Epub ahead of print] PMID: 22949651

Bogunovic, D., Byun, M., Durfee, LA., Abhyankar, A., Sanal., O., Mansouri, D., Salem, S., Radovanovic, I., Grant, AV., Adimi, P., Mansouri, N., Okada, S., Bryant, VL., Kong, X-F., Kreins, A., Boisson, B., Khalilzadeh, S., Ozcelik, U., Darazam, A.I., Schoggins, JW., Rice, CM., Al-Muhsen, S., Vogt, G., Puel, A., Bustamante, J., **Gros, P.**, Huibregtse, JM., Abel, L., Boisson-Dupuis, S. and Casanova, J-L. "Impaired IFN γ immunity and mycobacterial disease in humans with inherited ISG15 deficiency" *Science.* 337(6102):1684-8, 2012 PMID: 22859821

HALLETT, Michael, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hallett%20M%22%20%5BAuthor%5D%20cancer>

Mourskaia AA, Amir E, Dong Z, Tiedemann K, Cory S, Omeroglu A, Bertos N, Ouellet V, Clemons M, Scheffer GL, Park M, **Hallett MT**, Komarova SV, Siegel PM. (2012) ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. *Breast Cancer Res.* 2012 Nov 22;14(6):R149. [Epub ahead of print] PMID: 23174366 [PubMed - as supplied by publisher]

Provençal N, Suderman MJ, Guillemin C, Massart R, Ruggiero A, Wang D, Bennett AJ, Pierre PJ, Friedman DP, Côté SM, **Hallett MT**, Tremblay RE, Suomi SJ, Szyf M. (2012) The signature of maternal rearing in the methylome in rhesus macaque prefrontal cortex and T cells. *J Neurosci.* 2012 Oct 31;32(44):15626-42. doi: 10.1523/JNEUROSCI.1470-12.2012.

Pepin F, Bertos N, Laferrière J, Sadekova S, Souleimanova M, Zhao H, Finak G, Meterissian S, **Hallett MT** and Park M (2012) Gene expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes. *Breast Cancer Res.*, DOI: 10.1186/bcr3246 Submitted: 27 April 2012, Published: 20 August 2012 22906178

Suderman M, McGowan P.O, Sasaki A, Huang T.C.T, **Hallett M**, Meaney M.J, Turecki G. and Szyf M (2012) Conserved epigenetic sensitivity to early life experience in the rat and human hippocampus. *Proc Natl Acad Sci U S A.* 2012 Oct 16;109 Suppl 2:17266-72. doi: 10.1073/pnas.1121260109. Epub 2012 Oct 8. PNAS, to appear.

Pla-Roca M, Leulmi RF, Tourekhanova S, Bergeron S, Laforte V, Moreau E, Gosline SJ, Bertos N, **Hallett MT**, Park M, Juncker D. (2011) Antibody colocalization microarray: A scalable technology for multiplex protein analysis in complex samples. *Mol Cell Proteomics.* 2011 Dec 14. [Epub ahead of print] 2012 Apr;11(4):M111.011460. Epub 2011 Dec 14.22171321

JONES, Russell, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jones%20RG%22%5BAuthor%5D>

Christie, D.A., Mitsopoulos, P., Blagih, J., Dunn, S.D., St.-Pierre, J., **Jones, R.G.**, Hatch, G.M., and Madrenas, J. (2012). SLP-2 deficiency in T cells is associated with impaired mitochondrial respiration and defective CD4⁺ T cell responses. *J. Immunol.* 189(9): 4349 – 4360. PMID: 23028053.

Goodman Cancer Research Centre Annual Report 2012

Blagih, J., Krawczyk, C.M., and ****Jones, R.G.** (2012). LKB1 and AMPK: Central regulators of lymphocyte metabolism and function. *Immunol. Rev.* 249(1): 59 – 71. PMID: 22889215.

Blagih, J. and ****Jones, R.G.** (2012). Polarizing macrophages through reprogramming of glucose metabolism. *Cell Metab.* 15(6): 793 – 795. PMID: 22682218.

McCAFFREY, Luke, Dr.

URL: <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=mccaffrey+l%5BAuthor%5D>

McCaffrey, L., Macara, I.G. (2012) Signaling Pathways in Cell Polarity. *Cold Spring Harb Perspect Biol.* 1;4(6). *I co-authored the review with Dr. Ian Macara.*

McCaffrey, L., Montalbano, J., Mihai, C., Macara, I.G. (2012) Loss of the Par3 Polarity Protein Promotes Invasion through aPKC-dependent Induction of Stat3. *Cancer Cell.* 13;22(5):601-14. *I conceived the experiments, contributed 12/14 figures and co-wrote the paper. JM contributed 2/14 figures. CM performed experiments for the revision. IGM conceived experiments and co-wrote the paper. All revisions were completed in my lab at McGill. ICorresponding author. *Member of my lab at McGill.*

MULLER, William, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Muller%20WJ%22%5bAuthor%5d%20McGill>

Ling, C., Su, V., Zuo, D.-M., and Muller, W.J. (2012). Loss of 14-3-3 σ tumor suppressor is a critical event in ErbB2-mediated tumor progression. *Cancer Discovery* 2, 68-81. PMID 22585169

Marcotte, R., Smith, H, Sanguin-Gendreau, V., McDonough, R., and Muller, W.J. (2012). Mammary epithelial disruption of c-Src impairs cell cycle progression and tumorigenesis. *PNAS* 109, 2808-2013. PMID 21628573

Li, J. Karaplis, A. C., Huang, D. C., Siegel, P. M., Camirand, A., Yang X.F., Muller, W.J. and Kremer, R. (2012). PTHrP drives breast tumor initiation, progression and metastasis in mice and is a potential therapy target. *JCI* 121.4655-4669. PMID 22056386

Ursini-Siegel, J., Hardy, W.R., Zheng, Y., Zuo, D.-M., Zhang, C., Podmore, L. Pawson, T., and Muller, W. J. (2012). The ShcA SH2 domain engages a PI-3K signalling complex and promotes breast cancer cell survival. *Oncogene* 2012 Nov 29;31(48):5038-44. Epub 2012 Jan 30. PMID 22286768

Klimacakova, E., Chenard, V., McGuirk, S., Germain, D., Avizonis, D., Muller, W. J., and St-Pierre, J. (2012). PGC-1 α promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply. *Cancer Res.* 72, 1538-1546. PMID 22266114

Biomel, P.J., Sminova, T., Zhou, Z. N., Wycoff, J., Park, H. I., Coniglio, S. J., Patel, P., Qian, B. Z., Stanley, E. R., Bresnick, A. R., Cox D., Pollard, J. W., Muller, W. J., Condeellis, J. and Segall, J. E. (2012). Contribution of CXCL12 secretion to invasion of breast cancer cells. *Breast Cancer Research* 14, 23. PMID 22314082

Lahlou, H., Sanguin-Gendreau, V., Frame, M.C., and Muller, W. J. (2012). Focal Adhesion Kinase

Goodman Cancer Research Centre Annual Report 2012

contributes to proliferative potential of ErbB2 mammary tumor cells but is dispensable for ErbB2 mammary tumor induction *in vivo*. Breast Cancer Research 14, 36. PMID 22373082

Kurley, S., Bierie, B., Carnahan, R. H., Lobdell, N.A., Davis, M. A., Hofmann, I., Moses, H.L. **Muller, W. J.** and Reynolds, A. B. (2012) P120-catenin is Essential for Terminal End Bud Function and Mammary Morphogenesis. Development 139, 1754-1764. PMID 22461563

Vaught, D.B., Stanford, J.C., Young, C., Hicks, D J., Wheeler, F., Rinehart, C., Sanchez, V., Koland, J., **Muller, W.J.**, Arteaga, C. L., and Cook, R.S. (2012). HER3 is required for HER2-induced pre-neoplastic changes to the breast epithelium and tumor formation. Cancer Res. 72, 2672-2682. PMID 22461506

Lahlou, H., T. Muller, Sanguin-Gendreau, V., Birchmeier, C. and **Muller, W.J.**, (2012). Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis. Cancer Res. 72, 12, 3080-3090. PMID 22665265

Jansen, G. Maattanen, P., Denisov, A., Scarffe, L., Schade, B., Balglu, H., Dejgaard, K., Chen, L.Y., **Muller, W. J.**, Gehring, K., and Thomas, D. (2012). An Interaction Map of ER Chaperones and Foldases. Mol. Cell. Prot. 11, 710-723. PMID 22665516

Uttermark, T*, Rao, T*, Cheng, H, Wang, Q., Lee, S.H., Wang, C.Z., Iglehart, J. D., Roberts, T., **Muller, W.J.***, and Zhao, J.* (2012). The p110 α and p110 β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes and Dev. 26, 1573-1586 *These authors contributed equally to the work.

Wang, Q, Li-S-H, Wang. H/, Xiao, Y., Sahin, O, Brady, S.W., Li, P., Ge, H., Jaffe, E., **Muller, W.J.**, Hortobagyi, G, and Yu, D. (2012). Concomitant targeting of tumor cells and induction of T cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res. 72, 4417-4428.

Hudson, T.S., Carlson, B.A., Hoeneroff, M.J., Young, H.A., Sordillo, L., **Muller, W.J.**, Hatfield, D.L., and Green, J. E. (2012). Selenoproteins reduce susceptibility to DMBA-induced mammary carcinogenesis. Carcinogenesis 33, 1225-1230.

Chang, H., Balenci, L., Okolowsky, N., **Muller, W.J.**, and Hamel, P. (2012). Mammary epithelial-restricted expression of activated c-Src rescues the block to mammary gland morphogenesis due to the deletion of the C-terminus of Patched-1. Developmental Biology. 370, 187-197.

Ridgeway, R.A., Serrels, B., Mason, S., Kinnaird, A., Muir, M., **Muller, W.J.**, Sansom, O.J., and Bruton, V. G. (2012). Focal adhesion kinase is required for β -catenin induced mobilisation of epidermal stem cells (2012). Carcinogenesis 33, 2369-2376.

NEPVEU, Alain, Dr.

URL: [http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nepveu%20A%22\[Author\]%20Mcgill](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nepveu%20A%22[Author]%20Mcgill)

Vadnais, C., S. Davoudi, M. Afshin, R. Harada, R. Dudley, P.-L. Clermont, E. Drobetsky and **Alain Nepveu**. CUX1 Transcription Factor is Required for Optimal ATM/ATR-Mediated Responses to DNA Damage. Nucleic Acids Research, Feb 8, 2012: 1-13. 2012.

Hulea, L., and **Alain Nepveu**. CUX1 Transcription Factors: From Biochemical Activities and Cell-Based Assays to Mouse Models and Human Diseases. *Gene*, 497: 18-26. 2012.

Sansregret, L., and **Alain Nepveu**. La médecine personnalisée grâce aux signatures d'expression génique : l'exemple du cancer du sein. *Médecine Sciences Amérique*, 1(2):31-39. 2012.

Book chapter:

Harada, R. and **A. Nepveu**. Chromatin Affinity Purification. Ales Vancura (ed.), *Transcriptional Regulation: Methods and Protocols*, Methods in Molecular Biology, vol. 809:237-253. 2012.

PARK, Morag, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Park%20M%22%5bAuthor%5d%20McGill>

Pla-Roca M, Leulmi RF, Tourekhanova S, Bergeron S, Laforte V, Moreau E, Gosline SJC., Bertos N, Hallett M, **Park M**, Juncker D. Antibody Colocalization Microarray: A Scalable Technology for Multiplex Protein Analysis in Complex Samples. *Molecular and Cellular Proteomics*. 2012 Apr;11(4):M111.011460. Epub 2011 Dec 14.

Wang Y, Roche O, Xu C, Moriyama EH, Heir P, Chung J, Roos F, Chen E, Finak G*, Milosevic M, Wilson BC, Teh B, **Park M**, Irwin M, and Ohh M. Hypoxia promotes ligand-independent EGFR signalling via HIF-mediated upregulation of caveolin-1. *Proc. Natl. Acad. Sci. USA* 2012 Mar 27;109(13):4892-7. Epub 2012 Mar 12.

Lai AZ, Durrant M, Zuo D, Ratcliffe CD, **Park M**. Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer. *J Biol Chem*. 2012 Mar 9;287(11):8048-59.

Fathers K, Bell E, Rajadurai CV, Cory S, Zhao H, Mourskaia A, Zuo D, Madore J, Monast A, Mes-Masson AM, Grosset AA, Gaboury L, Hallett M, Siegel P, **Park M**. Crk adaptor proteins act as key signaling integrators for breast cancer growth and metastasis. *Breast Cancer Res*. 2012 May 8;14(3):R74.

Parachoniak CA, **Park M**. Dynamics of receptor trafficking in tumorigenicity. *Trends Cell Biol*. 2012 Mar 5. 2012 May;22(5):231-40. PMID:22397948

Rajadurai CV, Havrylov S, Zaoui K, Vaillancourt R, Stuible M, Naujokas M, Zuo D, Tremblay ML, **Park M**. Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia. *J Cell Sci*. 2012 Feb 24. *J Cell Sci*. 2012 Jun 15;125(Pt 12):2940-53.

Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresch DA, **Park M**, Bergers G. VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex. *Cancer Cell*. 2012 Jul 10;22(1):21-35.

Pepin F., Laferrière J, Bertos NR., Sadekova S., Souleimanova S., Zhao H., Finak G., Meterissian S., Hallett M., **Park M**. Gene expression profiling of breast cancer microvasculature identifies distinct tumor vascular subtypes. *Breast Cancer Research*, 2012 Aug 20;14(4):R120.

Goodman Cancer Research Centre Annual Report 2012

Emily S. Bell and **Park M.** "Models of Crk adaptor proteins in cancer" *Genes & Cancer*, Epub 2012 Oct 7, doi: 10.1177/1947601912459951

PAUSE, Arnim, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Pause%20A%20%5bAuthor%5d>

Tee, A.R., **Pause, A.** Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin. *Fam Cancer*. 2012, Oct 25.

Kharitidi,K., Apaja,P., Manteghi,S., Gingras,M-C., Lukacs,G. and **Pause, A.** 2012. Characterization of endosome specific ESCRT complex involved in integrin $\alpha 5$ trafficking and cell migration. Submitted.

Yan,M., Gingras,M-C., Dunlop,E., Nouet,Y., Jones,R., Tee,A. and **Pause, A.** 2012. AMPK drives metabolic adaptation in normoxia via HIF activation through ROS production derived from mitochondrial biogenesis. Submitted.

Nouet,Y., Possik.E., Jalali,Z., Yang,M. and **Pause, A.** 2012. The tumor suppressor folliculin is a novel regulator of AMPK sensing oxidative and metabolic stress. Submitted.

Uniacke,J., Holterman,C.E., Lachance,G., Franovic,A., Jacob,M.D., Fabian,M.R., Payette,J., Holcik,M., **Pause,A.**, Lee,S. 2012. An oxygen-regulated switch in the protein synthesis machinery. *Nature*. 486:126-129

Jonasch,E., Futreal,P.A., Davis,I.J., Bailey,S.T., Kim,W.Y., Brugarolas,J., Giaccia,A.J., Kurban,G., **Pause,A.**, Frydman,J., Zurita,A.J., Rini,B.I., Sharma,P., Atkins,M.B., Walker,C.L., Rathmell,W.K. 2012. State of the science: an update on renal cell carcinoma. *Mol Cancer Res*. 10:859-880.

PELLETIER, Jerry, Dr.

URL: [http://www.ncbi.nlm.nih.gov/pubmed?term=Pelletier%2C%20Jerry\[Full%20Author%20Name\]](http://www.ncbi.nlm.nih.gov/pubmed?term=Pelletier%2C%20Jerry[Full%20Author%20Name])

Rodrigo, C.M., Cencic, R., Roche, S.P., **Pelletier, J.** and Porco Jr., J.A. (2012). Synthesis of Rocaglamide hydrozamates and related compounds as eukaryotic translation inhibitors: Synthetic and biological studies. *J. Med. Chem.* 55: 558-562.

Mills, J.R., Malina, A., and **Pelletier, J.** (2012). Inhibiting Mitochondrial-Dependent Proteolysis of Mcl-1 Promotes Resistance to DNA Damage. *Cell Cycle*. 11: 88-98.

Nasr, Z., Robert, F., Porco Jr., J.A., Muller, W.J., and **Pelletier, J.** (2012). eIF4F suppression in breast cancer affects maintenance and progression. *Oncogene*. doi:10.1038/onc.2012.105

Robert, F., Mills, J., Agenor, A., Wang, D., Di Marco, S., Cencic, R., Tremblay, M., Gallouzi, I.E., Hekimi, S., Wing, S.S., and **Pelletier, J.** (2012). Targeting protein synthesis in a Myc/mTOR-driven model of Anorexia-Cachexia Syndrome Delays Its Onset and Prolongs Survival. *Cancer Res*. 72: 747-756.

Goodman Cancer Research Centre Annual Report 2012

Lin, C.-J., Nasr, Z., Premssirirut, P.K., Porco, J.A. Jr., Hippo, Y., Lowe, S.W., and **Pelletier, J.** (2012). Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. *Cell Reports*. 1: 325-333.

Sun, Y., Atas, E., Lindqvist, L., Sonenberg, N., **Pelletier, J.**, and Meller, A. (2012). The eukaryotic initiation factor eIF4H facilitates loop-binding, repetitive RNA unwinding by the eIF4A DEAD-box helicase. *NAR*. 40: 6199-6207.

Scuoppo, C., Miething, C., Lindqvist, L., Reyes, J., Ruse, C., Appelmann, I., Yoon, S., Krasnitz, A., Teruya-Feldstein, J., Pappin, D., **Pelletier J.**, & Lowe, S.W. (2012). A tumor suppressor network relying on the polyamine-hypusine axis. *Nature*. 487: 244 – 248.

Di Marco, S., Cammas, A., Lian, X., Kovacs, E.N., Mazroui, R., **Pelletier, J.**, and Eddine Gallouzi, I. (2012). The eIF4A inhibitor Pateamine A prevents the onset of cytokine-induced muscle wasting. *Nature Communication*. 3: 896.

Galicia-Vázquez, G., Cencic, R., Robert, F., Agenor, A.Q., and **Pelletier, J.** (2012). A Cellular Response Linking eIF4AI Activity to eIF4AII Transcription. *RNA*, 18: 1373-1384.

SHORE, Gordon, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shore%20GC%22%5BAuthor%5D%20McGill>

Natasha C. Chang; Mai Nguyen; Johanne Bourdon; Paul-Andre Risse; James Martin; Gawiyou Danialou; Rosario Rizzuto; Basil J. Petrof; **Gordon C. Shore**. Bcl-2-Associated Autophagy Regulator Naf-1 Required for Maintenance of Skeletal Muscle *Human Molecular Genetics* 2012; doi: 10.1093/hmg/dd5048

Chang NC, Nguyen M, **Shore GC**. BCL2-CISD2: An ER complex at the nexus of autophagy and calcium homeostasis? *Autophagy*. 2012 May 1;8(5):856-7. doi: 10.4161/auto.20054.

Klionsky DJ et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*. 2012 Apr;8(4):445-544.

SIEGEL, Peter, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Siegel%20PM%20%5bAuthor%5d>

A.A. Mourskaia, E. Amir , Z. Dong, K. Tiedemann, S. Cory, A. Omeroglu, N. Bertos, V. Ouellet, M. Clemons, G.L. Scheffer, M. Park, M. Hallett, S.V. Komarova, **P.M. Siegel**. (2012). ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. *Breast Cancer Res*. 14(6): R149.

X.Y. Liu, N. Gerges, A. Korshunov, N. Sabha, D.A. Khuong-Quang, A.M. Fontebasso, A. Fleming, D. Hadjadj, J. Schwartzentruber, J. Majewski , Z. Dong, **P. Siegel**, S. Albrecht, S. Croul, D.T. Jones, M. Kool, M. Tonjes, G. Reifenberger, D. Faury, G. Zadeh, S. Pfister and N. Jabado. (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. *Acta Neuropathol*. 124(5):615-625.

S. Tabariès, F. Dupuy, Z. Dong, A. Monast, M.G. Annis, J. Spicer, L.E. Ferri, A. Omeroglu, M. Basik,

Goodman Cancer Research Centre Annual Report 2012

- E. Amir, M. Clemons and **P.M. Siegel**. (2012) Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. *Mol. Cell. Biol.* 32(15): 2979-91.
- K.E. Fathers, E. Hanson , C.V. Rajadurai , S. Cory , H. Zhao , A. Mourskaia , D. Zuo , J. Madore, A. Monast , A-M. Mes-Masson, A-A Grosset, L. Gaboury, M. Hallett, **P.M. Siegel** and M. Park. (2012). Crk adaptor proteins act as key signaling integrators for breast cancer growth and metastasis. *Breast Cancer Res.* 14(3): R74.
- V. Ouellet and **P.M. Siegel** (2012). CCN3 Modulates Bone Turnover and is a *Novel* Regulator of Skeletal Metastasis. *J Cell Commun Signal.* 6(2): 73-85.
- J. Schwartzenuber, A. Korshunov, X-Y. Liu, D.T.W. Jones, E. Pfaff, K. Jacob, D. Sturm, A. M Fontebasso, D-A. Khuong Quang, M. Tönjes, V. Hovestadt, S. Albrecht, A. Nantel, C. Konermann, N. Jäger, T. Rausch, M. Ryzhova, J. Korbel, T. Hielscher, P. Hauser, M. Garami, A. Klekner, L. Bognar, M. Ebinger, M.U. Schuhmann, W. Scheurlen, A. Pekrun, M. Frühwald, W. Roggendorf, C. Kramm, M. Dürken, J. Atkinson, P. Lepage, A. Montpetit, M. Zakrzewska, K. Zakrzewski, P.P. Liberski, Z. Dong, **P. Siegel**, A.E. Kulozik, M. Zapatka, A. Guha, D. Malkin, J. Felsberg, G. Reifenberger, A. von Deimling, K. Ichimura, V. Peter Collins, H. Witt, T. Milde, O. Witt, C. Zhang, P. Castelo-Branco, P. Lichter, D. Faury, U. Tabori, C. Plass, J. Majewski, S.M. Pfister, N. Jabado. (2012) Exome sequencing identifies frequent driver mutations in histone H3.3 and ATRX-DAXX in pediatric glioblastoma. *Nature.* 482(7384):226-231.

SONENBERG, Nahum, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Sonenberg%20N.%20%5bAuthor%5d%20McGill>

- Pons, B., Armengol, G., Livingstone, M., Lopez, L., Coch, L., **Sonenberg, N.**, and Ramon Y Cajal, S. (2012) Association between LRRK2 and 4E-BP1 protein levels in normal and malignant cells. *Oncol Rep* 27(1), 225-231.
- Nogueira, V., Sundararajan, D., Kwan, J.M., Peng, X.D., Sarvepalli, N., **Sonenberg N.**, and Hay, N. (2012) Akt-dependent Skp2 mRNA translation is required for exiting contact inhibition, oncogenesis, and adipogenesis. *EMBO J* 31(5), 1134-1146.
- Fabian, M.R., Cieplak, M., Frank, F., Morita, M., Green, J., Srikumar, T., Nagar, B., Yamamoto, T., Raught, B., Duchaine, R.F., and **Sonenberg, N.** (2012) miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT. *Nature Struct Mol Biol* 19(3), 364.
- Lin, J., Fabian, M., **Sonenberg, N.**, and Meller, A. (2012) Nanopore detachment kinetics of poly(A) binding proteins from RNA molecules reveals the critical role of C-terminus interactions. *Biophys J* 102(6), 1427-1434.
- Fujiwara, T., Fukao, A., Sasano, Y., Matsuzaki, H., Kikkawa, U., Imataka, H., Inoue, K., Endo, S., **Sonenberg, N.**, Thoma, C., and Sakamoto, H. (2012) Functional and direct interaction between the RNA binding protein HuD and active Akt1. *Nucleic Acids Res* 40(5), 1944-1953.
- Penney, J., Tsurudome, K., Liao, E.H., Elazzouzi, F., Livingstone, M., Gonzalez, M., **Sonenberg, N.**, and Haghghi, A.P. (2012) TOR is required for the retrograde regulation of synaptic homeostasis at

Goodman Cancer Research Centre Annual Report 2012

the *Drosophila* neuromuscular junction. *Neuron* 74(1), 166-178.

- Srivastava, T., Fortin, D.A., Nygaard, S., Kaech, S., **Sonenberg, N.**, Edelman, A.M., and Soderling, T.R. (2012) Regulation of neuronal mRNA translation by CaM-kinase I phosphorylation of eIF4GII. *J Neurosci* 32(16), 5620-5630.
- Chenoweth, M.J., Mian, M.F., Barra, N.G., Alain, T., **Sonenberg, N.**, Bramson, J., Lichty, B.D., Richards, C.D., Ma, A., and Ashkar, A.A. (2012) Il-15 can signal via IL-15R α , JNK, and NF- κ B to drive RANTES production by myeloid cells. *J. Immunol* 188(9), 4149-4157.
- Li, Z., Miard, S., Laplante, M., **Sonenberg, N.**, and Picard, F. (2012) Insulin stimulates IGFBP-2 expression in 3T3-L1 adipocytes through the PI3K/mTOR pathway. *Mol Cell Endocrinol* 358(1):63-68.
- Fonseca, B.D., Diering, G.H., Bidinosti, M.A., Dalal, K., Alain, T., Balgi, A.D., Forestieri, R., Nodwell, M., Rajadurai, C.V., Gunaratnam, C., Tee, A.R., Duong, F., Andersen, R.J., Orłowski, J., Numata, M., **Sonenberg, N.**, and Roberge, M. (2012) Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. *J Biol Chem* 287(21),17530-17545.
- Kundu, P., Fabian, M.R., **Sonenberg, N.**, Bhattacharyya, S.N., and Filipowicz, W. (2012) HuR protein attenuates miRNA-mediated repression by promoting miRISC dissociation from the target RNA. *Nucleic Acids Res* 40(11), 5088-5100.
- Sun, Y., Atas, E., Lindqvist, L., **Sonenberg, N.**, Pelletier, J., and Meller, A. (2012) The eukaryotic initiation factor eIF4H facilitates loop-binding, repetitive RNA unwinding by the eIF4A DEAD-box helicase. *Nucleic Acids Res* 40(13), 6199-6207.
- Herdy, B., Jaramillo, M., Svitkin, Y.V., Rosenfeld A.B., Kobayashi, M., Walsh, D., Alain, T., Sean, P., Robichaud, N., Topisirovic, I., Furic, L., Dowling, R.J., Sylvestre, A., Rong, L., Colina, R., Costa-Mattioli, M., Fritz, J.H., Oliver, M., Brown E., Mohr, I., and **Sonenberg N.** (2012) Translational control of the activation of transcription factor NF- κ B and production of type I interferon by phosphorylation of the translation factor eIF4E. *Nat Immunol* 13(6), 543-550.
- Larsson, O., Morita, M., Topisirovic, I., Alain, T., Blouin, M.J., Pollak, M., and **Sonenberg, N.** (2012) Distinct perturbation of the translome by the antidiabetic drug metformin. *Proc Natl Acad Sci* 109(23), 8977-8982.
- Yanagiya, A., Suyama, E., Adachi, H., Svitkin, Y.V., Aza-Blanc, P., Imataka, H., Mikami, S., Martineau, Y., Ronai, Z.A., and **Sonenberg, N.** (2012) Translational homeostasis via the mRNA cap-binding protein, eIF4E. *Mol Cell* 46(6), 847-858.
- Tettweiler, G., Kowanda, M., Lasko, P., **Sonenberg, N.**, and Hernandez, G. (2012) The distribution of eIF4E-Family members across Insecta. *Comp Funct Genomics* 2012, 960420.
- Frank, F., Hauver, J., **Sonenberg, N.**, and Nagar, N. (2012) Arabidopsis Argonaute MID domains use their nucleotide specificity loop to sort small RNAs. *EMBO J* 31(17), 3588-3595.
- Morita, M., Ler, L.W., Fabian, M.R., Siddiqui, N., Mullin, M., Henderson, V.C., Alain, T., Fonseca,

Goodman Cancer Research Centre Annual Report 2012

B.D., Karashchuk, G., Bennett, C.F., Kabuta, T., Higashi, S., Larsson, O., Topisirovic, I., Smith, R.J., Gingras, A.C., and **Sonenberg, N.** (2012) A novel 4EHP-GIGYF2 translational repressor complex is essential for mammalian development. *Mol Cell Biol.* 32(17), 3585-3593.

Hernandez, G., Han, H., Gandin, V., Fabian, L., Ferreira, T., Zuberek, J., **Sonenberg, N.**, Brill, J.A., and Lasko, P. (2012) Eukaryotic initiation factor 4E-3 is essential for meiotic chromosome segregation, cytokinesis and male fertility in *Drosophila*. *Development* 139(17), 3211-3220.

Alain, T., Morita, M., Fonseca, B.D., Yanagiya, A., Siddiqui, N., Bhat, M., Zammit, D., Marcus, V., Metrakos, P., Voyer, L.A., Gandin, V., Liu, Y., Topisirovic, I., and **Sonenberg, N.** (2012) eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. *Cancer Res* 72(24), 6468-6476.

Books (Editor):

N. Sonenberg, M.B. Mathews and J.W.B. Hershey, eds (2012). *Perspectives in Biology: Translational Control*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

Reviews and Book Chapters:

Fabian, M.R., and **Sonenberg N.** (2012) The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. *Nat Struct Mol Biol* 19(6), 586-593.

Sonenberg, N., and Filipowicz, W. (2012) Retrospective. Aaron Shatkin (1934-2012). *Science* 337(6092), 309. PMID: 22822142

Mohr, I., and **Sonenberg, N.** (2012) Host translation at the nexus of infection and immunity. *Cell Host Microbe* 12(4), 470-483. PMID: 23084916

Hershey, J.W., **Sonenberg, N.**, and Mathews, M.B. (2012) Principles of translational control: an overview. *Cold Spring Harb Perspect Biol.* 4(12). PMID: 23209153

ST-PIERRE, Julie, Dr.

URL: <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=St+Pierre%2C+Julie%5BFull+Author+Name%5D>

Deblois, G., **St-Pierre, J.** and Giguère, V. (2012). The PGC-1/ERR signaling axis in cancer. *Oncogene* Dec 3 (doi: 10.1038/onc.2012.529). *Impact factor: 6.4; Pubmed ID: 23208510. This review covers the recent development in the understanding of the metabolic roles of ERRs and PGC-1s in cancer. I participated to the writing of the sections on PGC-1s and to the elaboration of novel concepts and future research directions presented in the manuscript.*

Austin, S. and **St-Pierre, J.** (2012). PGC-1 α and mitochondrial metabolism: emerging concepts and relevance in aging and neurodegenerative disorders. *Journal of Cell Science* 125, 4963-4971. *Impact factor: 6.1; Pubmed ID: 23277535*

Zakikhani, M., Bazile, M., Hashemi, S., Javeshghani, S., Avizonis, D., **St-Pierre, J.** and Pollak, M.N. (2012). Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin. *PLOS one* Nov 21 (doi: 10.1371/journal.pone.0049513). *Impact factor: 4.1; Pubmed ID: 23185347. I assisted in the*

Goodman Cancer Research Centre Annual Report 2012

conception, execution and interpretation of the cellular respiration measurements. Also, I wrote the corresponding sections in the manuscript.

Javeshghani, S., Zakikhani, M., Austin, S., Bazile, M., Blouin, M.J., Topisirovic, I., **St-Pierre, J.** and Pollak, M.N. (2012). Carbon source and myc expression influence the antiproliferative actions of metformin. *Cancer Research* 72 (23), 6257-6267. *Impact factor: 7.9; Pubmed ID: 23041548. We performed all the respiration experiments presented in the manuscript and wrote the corresponding sections.*

Christie, D.A., Mitsopoulos, P., Blagih, J., Dunn, S.D., **St-Pierre, J.**, Jones, R.G., Hatch, G.M., Madrenas, J. (2012). Stomatin-like Protein 2 Deficiency in T cells is associated with altered mitochondrial respiration and defective CD4+ T cell responses. *Journal of Immunology* 189 (9), 4349-4360. *Impact factor: 5.8; Pubmed ID: 23028053. I assisted in the conception, execution and interpretation of the cellular respiration measurements. Also, I edited the corresponding sections in the manuscript.*

Klimcakova, E., Chénard, V., McGuirk, S., Germain, D., Avizonis, D., Muller, W.J. and **St-Pierre, J.** (2012). PGC-1 α promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply. *Cancer Research* 72 (6), 1538-1546. *Impact factor: 7.9; Pubmed ID: 22266114*

St-Pierre, J. and Tremblay, M.L. (2012). Modulation of leptin resistance by protein tyrosine phosphatases. *Cell Metabolism* 15 (3), 292-297. The two authors are joint corresponding authors. *Impact factor: 13.7; Pubmed ID: 22405067. This review presents the role of specific phosphatases in the development of leptin resistance. Dr. Tremblay took a leading role for the sections of the manuscript covering signaling, while I took charge of the sections on leptin resistance and metabolism. Dr. Tremblay and myself wrote the manuscript and elaborated the figures together. We are both corresponding authors on this review.*

TEODORO, Jose, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Teodoro%20J.G%20%5bAuthor%5d>

S. Assadian, W. El-Assaad, X.Q. Wang, Y., P.O. Gannon, V. Barrès, M. Latour, A.M. Mes-Masson, F. Saad, Y. Sado, J. Dostie and **J.G. Teodoro.** (2012) The p53 tumor suppressor inhibits angiogenesis by inducing expression and processing of collagen IV into the anti-angiogenic protein, arresten. *Cancer Research*. Mar; 72(5):1270-9.

TREMBLAY, Michel, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Tremblay%20ML%20%5bAuthor%5d>

Hardy S, Julien SG, **Tremblay ML.** Impact of oncogenic protein tyrosine phosphatases in cancer. *Agents Med Chem.* 2012 Jan;12(1):4-18.

Doody KM, Bussièrès-Marmen S, Li A, Paquet M, Henderson JE, **Tremblay ML.** T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis and subchondral bone resorption in mice. *Arthritis Rheum.* 2012 Mar;64(3):752-61.

Goodman Cancer Research Centre Annual Report 2012

Berdnikovs S, Pavlov VI, Abdala-Valencia H, McCary CA, Klumpp DJ, **Tremblay ML**, Cook-Mills JM. PTP1B deficiency exacerbates inflammation and accelerates leukocyte trafficking in vivo. *J Immunol.* 2012 Jan 15;188(2):874-84.

Robert F, Mills JR, Agenor A, Wang D, DiMarco S, Cencic R, **Tremblay ML**, Gallouzi IE, Hekimi S, Wing SS, Pelletier J. Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival. *Cancer Res.* 2012 Feb 1;72(3):747-56.

Lessard L, Labbé DP, Deblois G, Bégin LR, Hardy S, Mes-Masson AM, Saad F, Trotman LC, Giguère V, **Tremblay ML**. PTP1B Is an Androgen Receptor-Regulated Phosphatase That Promotes the Progression of Prostate Cancer. *Cancer Res.* 2012 Mar 15;72(6):1529-1537. Epub 2012 Jan 26.

Labbé DP, Hardy S, **Tremblay ML**. Protein tyrosine phosphatases in cancer: friends and foes! *Prog Mol Biol Transl Sci.* 2012;106:253-306.

Rajadurai CV, Havrylov S, Zaoui K, Vaillancourt R, Stuible M, Naujokas M, Zuo D, **Tremblay ML**, Park M. Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia. *J Cell Sci.* 2012 Feb 24. [Epub ahead of print]

St-Pierre J, **Tremblay ML**. Modulation of leptin resistance by protein tyrosine phosphatases. *Cell Metab.* 2012 Mar 7;15(3):292-7.

Brown JM, Xia J, Zhuang B, Cho KS, Rogers CJ, Gama CI, Rawat M, Tully SE, Uetani N, Mason DE, **Tremblay ML**, Peters EC, Habuchi O, Chen DF, Hsieh-Wilson LCA sulfated carbohydrate epitope inhibits axon regeneration after injury. *Proc Natl Acad Sci U S A.* 2012 Mar 27. [Epub ahead of print]

Vang T, Liu WH, Delacroix L, Wu S, Vasile S, Dahl R, Yang L, Musumeci L, Francis D, Landskron J, Tasken K, **Tremblay ML**, Lie BA, Page R, Mustelin T, Rahmouni S, Rickert RC, Tautz L. LYP inhibits T-cell activation when dissociated from CSK. *Nat Chem Biol.* 2012 Mar 18. [Epub ahead of print]

Kelly A. Pike¹, and **Michel L. Tremblay**¹. Regulating naïve and memory CD8 T cell homeostasis: a role for protein tyrosine phosphatases *FEBS J.* 2012 Mar 28. doi: 10.1111/j.1742-4658.2012.08587.x. [Epub ahead of print]

Elodie Gomez, Magali Vercauteren, Baptiste Kurtz, Antoine Ouvrard-Pascaud, Paul Mulder, Jean-Paul Henry, Marie Besnier, Aurélie Wagee, Rob Hooft Van Huijsduijnen, Michel L Tremblay, Remy Burcelin, Christian Thuillez and Vincent Richard. Reduction of heart failure by pharmacological inhibition or gene deletion of Protein Tyrosine Phosphatase 1B. *Journal of Molecular and Cellular Cardiology* 2012 Mar 15. [Epub ahead of print]

Wiede F., B. Shields, KS Chew, K. Kyparissoudis, C. van Vliet, S. Galic, **ML. Tremblay**, S. Russell, D. Godfrey, T. Tiganis. Strain-dependent differences in bone development, myeloid hyperplasia, morbidity and mortality in Ptpn2-deficient mice. *PLoS One.* 2012;7(5):e36703. Epub 2012 May 8

Horn KE, Xu B, Gobert D, Hamam BN, Thompson KM, Wu CL, Bouchard JF, Uetani N, Racine RJ, **Tremblay ML**, Ruthazer ES, Chapman CA, Kennedy TE (2012) Receptor Protein Tyrosine

Goodman Cancer Research Centre Annual Report 2012

Phosphatase Sigma Regulates Synapse Structure, Function and Plasticity. *J Neurochem. J Neurochem.* 2012 Apr 21. doi: 10.1111/j.1471-4159.2012.07762.x. [Epub ahead of print]

Mori J, Wang YJ, Ellison S, Heising S, Neel BG, **Tremblay ML**, Watson SP, Senis YA. Dominant Role of the Protein-Tyrosine Phosphatase CD148 in Regulating Platelet Activation Relative to Protein-Tyrosine Phosphatase-1B. *Arterioscler Thromb Vasc Biol.* 2012 Oct 11. [Epub ahead of print]

de Chantemèle EJ, Ali MI, Mintz JD, Rainey WE, **Tremblay ML**, Fulton DJ, Stepp DW. Increasing Peripheral Insulin Sensitivity by Protein Tyrosine Phosphatase 1B Deletion Improves Control of Blood Pressure in Obesity. *Hypertension.* 2012 Nov;60(5):1273-9. doi: 10.1161/HYPERTENSIONAHA.112.196295. Epub 2012 Oct 8.

Bourdeau A., S. Trop, KM. Doody, M. Cruz, DJ. Dumont, **ML. Tremblay**. Inhibition of T cell protein tyrosine phosphatase (TC-PTP) enhances IL-18-dependent hematopoietic progenitor expansion. *Stem Cells.* 2012 Nov 8. doi: 10.1002/stem.1276. [Epub ahead of print]

YANG, Xiang-Jiao, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Yang%20XJ.%20%5bAuthor%5d%20Montreal>

Avvakumov, N., Lalonde, M. E., Saksouk, N., Paquet, E., Glass, K. C., Landry, A. J., Doyon, Y., Cayrou, C., Robitaille, G. A., Richard, D. E., **Yang, X. J.**, Kutateladze, T. G. and Cote, J. (2012) Conserved molecular interactions within the HBO1 acetyltransferase complexes regulate cell proliferation. *Mol Cell Biol* 32, 689-703.

Campeau, P. M., Kim, J. C., Lu, J. T., Schwartzentruber, J. A., Abdul-Rahman, O. A., Schlaubitz, S., Murdock, D. M., Ming-Ming Jiang, M. M., Edward J Lammer, E. J., Enns, G. M., Rhead, W. J., Rowland, J., Robertson, S. P., Cormier-Daire, V., Bainbridge, M. N., **Yang, X. J.**, Gingras, M. G., Richard A Gibbs, R. A., Rosenblatt, D. S., Majewski, J. and Lee, B. H. (2012) Mutations in KAT6B, encoding a histone acetyltransferase, cause genitopatellar syndrome. *Am. J. Hum. Genet.*, 90, 282-289.

Xu, C., Jin, J., Bian, C., Lam, R., Tian, R., Weist, R., You, L., Nie, J., Bochkarev, A., Tempel, W., Tan, C.S., Wasney, G.A., Vedadi, M., Gish, G.D., Arrowsmith, C.H., Pawson, T., **Yang, X.J.**, and Min, J. (2012) Sequence-specific recognition of a PxLPxI/L motif by an ankyrin repeat tumbler lock. *Science Signaling*, 5, ra39.

Ali, M., Yan, K., Lalond, M.E., Degerny, C., Rothbart, S.B., Strahl, B.D., Cote, J., **Yang, X.J.**, and Kutateladze, T.G. (2012) Tandem PHD fingers of MOZ/MORF acetyltransferases display selectivity for acetylated histone H3 and are required for chromatin association. *J. Mol. Biol.* 424, 328-38.

Invited Reviews:

Yan, K., Wu, C.J., Pelletier, N., and **Yang, X.J.** (2012) Expression and assembly of multisubunit histone acetyltransferase complexes in insect cells. *Methods Mol. Biol.* 809, 445-64.

You, L., Nie, J., Sun, W.J., Zheng, Z.Q., and **Yang, X.J.** (2012) Lysine acetylation: enzymes, bromodomains, and links to different diseases. *Essays in Biochemistry* 52, 1-12.

ZANNIS-HADJOPOULOS, Maria, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Zannis-Hadjopoulos%20M%20%5bAuthor%5d>

Andersen, SD, Rampakakis, E., El-Shemerly, M., Luhn, P., Nielsen, FC., Du, YH., May, A., Bohr, V.A., Fu, H., Ferrari, S., **Zannis-Hadjopoulos, M.** and Rasmussen, LJ. (2012). DNA repair protein human exonuclease 1 (hEXO1) interacts with regulatory checkpoint proteins 14-3-3 - a novel protein interaction network between DNA repair and cell cycle control DNA Repair (Amst);11(3):267-77.

Di Paola, D., and **Zannis-Hadjopoulos, M.** (2012). Comparative analysis of pre-replication complex (pre-RC) proteins at replication origins of transformed and normal cells. J. Cell. Biochem., 113: 1333–1347.

Di Paola, D., Rampakakis, E., Chan, MK., **Zannis-Hadjopoulos M.** (2012). Differential chromatin structure encompassing replication origins in transformed and normal cells. Genes & Cancer 3: 152-176.

ZOGOPOULOS, George, Dr.

URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=Zogopoulos%20G%20%5BAuthor%5D%20>

Al-Sukhni W., Joe S., Lionel A.C., Zwingerman N., **Zogopoulos G.**, Marshall C.R., Borgida A., Holter S., Gropper A., Moore S., Bondy M., Klein A.P., Petersen G.M., Rabe K.G., Schwartz A.G., Syngal S., Scherer S.W., Gallinger S. Identification of germline genomic copy number variation in familial pancreatic cancer. Hum Genet. *Hum Genet.*131(9):1481-94, 2012.

APPENDIX V

Involvement in the Community 2012

BEAUCHEMIN, Nicole

Committees

Co-director of the McGill Integrated Cancer Research Training Program (MICRTP), jointly funded by CIHR and FRSQ. 56 investigators and 250 trainees. September 2006-present. THIS TASK REQUIRES ONE DAY/WEEK OF WORK.

Member of search committee for administrators in Goodman Cancer Research Centre, Sept. 5, 2012.

Coordinator of the Metastasis and Angiogenesis Research Group for the Goodman Cancer Research Centre (2008-2012).

Chair of the Training committee for the Goodman Cancer Research Centre, 2010-present.

Member of the Dept. of Oncology Financial Oversight committee. 2012-present.

Conference Organization

Chair and co-organizer of the Montreal International Symposium on Angiogenesis and Metastasis (MISAM 2013). Responsible for grant writing, scientific program and coordination of 2.5 day event for June 12-14 2013 for 150 Quebec, Canadian and international attendees.

I was also participating in the organization of the meeting Signalisation-Quebec in Trois-Rivières in 2012. This meeting brings together all researchers in Quebec using Molecular Signaling as a readout of their phenotypic experiments.

Grant Panels

Canadian Institutes for Health Research, 2011 – present, Chair: Cancer Progression and Therapeutics committee. This committee requires **10 days of work** other than reviewing. I make it a point to read and evaluate all grants submitted to our panel i.e. 90 grants/year.

Journal Reviews

at least 10 reviews for various journals/year

Community Outreach

Goodman Cancer Centre Public Forum, Organizer and Moderator for 2011-2012.

Goodman Cancer Centre Public Forum, Organizer and Moderator for 2012-2013.

Invited Presentations and Workshops

Queen's University, Dept. of Biochemistry, seminar, Kinston, ON, October 2012

Canadian Digestive Disease Week, Symposium, Feb. 2012

Signalisation-Québec, June 2012

22nd CEA International Symposium, Clermont-Ferrand, France, June 2012

40th annual meeting of International Society for Oncology and Biomarkers (ISOBM), Jerusalem, Israel, October 2012. KEYNOTE ADDRESS

BOUCHARD, Maxime

Goodman Cancer Research Centre Annual Report 2012

Ad hoc reviewer

NSERC, Dec 15, 2012

Editorial Boards

ISRN Nephrology, April 2012

Internal Committees

Member, Imaging facility, Life Science Complex, May 2004- present

Member, Histology facility committee, Life Science Complex, May 2004- present

Member, Financial Committee, Goodman Cancer Research Centre, May 2004- present

Member, Graduate Admission Committee, Biochemistry, Sept. 2004- present

Evaluate Ph.D. proposal of every graduate student registered in Biochemistry (1-2 days of student presentations per semester; over 60 students to date)

Decide on new programs and policies for the Biochemistry graduate program

Establish course requirements for newly admitted graduate students

Member, Executive Direction Committee, Division of Experimental Medicine, Faculty of Medicine, Jan. 2007- present. Decide on new Associate members to join in the Division; decide on policies and regulations for the Division.

Invited speaker

20th Meeting of the EUA section of Urological Research (ESUR), Anti-oncogenic role of Gata3 in prostate cancer. Oct. 25-27, 2012, Strasbourg, France

Conference: Immunity Epigenetics and Cancer, Gata3 in prostate development and cancer. Research Institute for Molecular Pathology, , Oct. 18-19, 2012, Vienna, Austria

Lady Davis Institute, Anti-oncogenic role of Gata3 in prostate cancer” March 22, 2012, Montreal

BRANTON, Philip

Panels, Boards and Councils

2006-present Chair, International Advisory Board, University Hospital Network, University of Toronto

2008-present Member, National Research Council Cancer Advisory Committee, Protein Therapeutics Group, Biotechnology Research Institute, Montreal, QC

2008-present Chair, Scientific Advisory Committee, Terry Fox Research Institute

2010-2012 Member, Lady Davis Research Institute Recruitment Search Committee

2010-present Chair, Jewish General-Goodman Cancer Research Centre Liaison Group

2010-present Member, Advisory Board, Canadian Tumour Repository Network

2010-present Member, Review Board, Integrated Cancer Research Sites (SIRIC), Institut national du cancer (INCa, Paris, France)

2011-present Member, Executive Committee, Goodman Cancer Centre, McGill University

2012 Chair, Review Committee for the Department of Medical Biophysics, University of Toronto

2012 Member, Alberta Innovates Health Solutions-Industry Partnered Translational Fund Advisory Panel

2012-2013 Chair, Brain Canada Training Award Panel

2012-present Chair, FRQS Committee for the creation of a Quebec Tumour Bank Network

2012-2013 Chair, Terry Fox Research Institute Consultation Committee on Program Project Grants

Internal Committees

Goodman Cancer Research Centre Annual Report 2012

2007-present Member, Department of Biochemistry Tenure Committee

2010-present Member, McGill University, Faculty of Medicine Honours & Awards Committee

DUCHAINE, Thomas

Invited speaker

Apr 2012 *Messenger RNA Deadenylation in MicroRNA-Mediated Silencing and RNAi*, Dept. Biology, NYU

Feb 2012 *microRNAs and 3' untranslated regions: a silent dialogue in the embryo*, Keystone International Symposium: Gene Silencing by Small RNAs

Journal Reviews

Molecular Cell, NSMB, Cell, RNA, Science, PNAS, DNA & Cell Biology, PloS One, PloS Genetics, Nucleic Acid Research, WIREs Developmental, Biology

Grant Reviews

2011-2012 CIHR, Molecular and Cellular Biology of Cancer, Member and Scientific Officer

2011-2012 FRSQ, Postdoctoral Fellowships, Member

Internal Committees

Goodman Cancer Research Centre finances committee, Member, April 2009 – present.

Faculty of Medicine internal grant review, Reviewer, Fall 2012.

Lady Davis (McGill) faculty recruitment committee, Invitee external member, 2 candidates in Fall 2012.

McGill Integrated Cancer Research Training Program (MICRTP), Interim co-Chair, August 2012.

Faculty of Medicine Graduate scholarships, Panelist, 2010, 2011, 2012.

Biochemistry Department Poster Day, Judge, 2011, 2012.

Graduate Admission Committee, PhD proposal Panel member, June 7, 2012, 3 reviews

GALLOUZI, Imed

Grant/Studentship Agencies

CIHR, permanent member of BCA panel as of Sept 2009 competition

FRSQ, Internal reviewer, Junior 1 salary awards, Feb. 2012

CIHR, NCIC, NSERC, NIH, CRC external reviewer

Alberta Heritage Found. for Medical Research, National Science Found., USA, American Federation for Aging Research and Prostate Cancer Foundation of Australia, Jesse's Journey Foundation, Heart and Stroke Foundation

Grant panels

Reviewer for a CRC (Canadian Research Chair) TierI, 2012

Regular reviewer for CRC (Canadian Research Chair) TierII. I reviewed several CRC TierII applications. 2006-present

NSERC, external reviewer for several Discovery Grants, 2005- present

External Reviewer for International Funding Agencies

Genesis Oncology Trust, New Zealand, external reviewer, 2012

Goodman Cancer Research Centre Annual Report 2012

Member of the scientific board of the American Federation for Aging Research (AFAR), Baltimore, Bethesda, USA. I serve as reviewer for several operating grants and postdoctoral Fellowships, 2009-present

Prostate Cancer Foundation of Australia (PCFA). external reviewer for several operating grants each round, 2009-to-present

Editorial Boards

Editor for PLoS One, 2011-present

Editor Aging, 2010-present

Invited speaker

Pateamine A, an Inhibitor of General Translation, Prevents Cachexia-Induced Muscle Wasting.
2 Seminars at the Universite de Laval, Quebec City, Quebec March 22-23, 2012.

Pateamine A, an Inhibitor of General Translation, Prevents Cachexia-Induced Muscle Wasting.
Seminar at the Meakins-Christie Laboratories, McGill University, Montreal, Quebec Sept 1, 2012.

Internal Committees

MICRTP, Studentship review, Goodman Cancer Research Centre, 2011-2012

Chair of the Graduate Advisory Committee (GAC), Department of Biochemistry, 2009-present

Member of the Graduate Advisory Committee (GAC), Department of Biochemistry, 2002-present

Member of the Departmental Tenure Committee (DTC), Department of Biochemistry, 2008-present

Member of Goodman Cancer Centre Space and Equipment Committee (Chair: Dr. Alain Nepveau), 2012-to-present

Member of Department of Biochemistry space committee, 2010-to-present

External Reviewer for Tenure dossiers

2012, Dr. Nadine Wiper-Bergeron, Department of Cellular and Molecular Medicine, University of Ottawa, ON, Canada

Activities outside McGill University

University of Taibah, Al-Madinah, Kingdom of Saudi Arabia

In 2011, Dr. David Thomas and I were approached by Dr. Kahled Al-Harbi from Taibah University, Al-Madinah Almunawwarah, Kingdom of Saudi-Arabia to help them in building the Centre for Genetics & Inherited Diseases (CGID). With Dr. Thomas I helped organizing several Visits for Dr. Al-Harbi to McGill and initiate contacts with University officials. I was also part of a team headed by Dr. D. Thomas that went to Al-Madinah in April 2012 to take part in the first international meeting for Genetics & Inherited Diseases that served as launching event for this project. This project is now underway and I am actively involved in the ongoing negotiation between McGill University, Taibah University and the CGID to put in place a service agreement with that will serve as a basis for this collaboration.

Invited to take part in the editing of the 1st Canadian edition of the Garrett and Grisham "Biochemistry" text book which will be launched in 2012

In 2010 I was approached by Nelson Education Ltd to help edit the "BIOCHEMISTRY" book for undergraduate students by Garrett and Grisham that will be launched as the first Canadian Edition of this book. I am one of the three professors that were hired for this task. The original task was to edit and update 10 to 11 chapters out of 32, with an emphasis of highlighting findings of Canadian scientists when appropriate. In addition, after my initial assessment of the content in various books covering Biochemistry, Molecular and Cellular Biology, I noticed that none of them, including the

Goodman Cancer Research Centre Annual Report 2012

Garrett & Grisham book, dedicates a chapter describing the mechanisms impacting gene expression at the posttranscriptional level. Therefore, I suggested to the editor to include such a chapter in the 1st Canadian edition of this book. The editors and my co-authors agreed and supported the idea.

The book is now at its final stage and will be launched in November 2012. I completed the new chapter that was reviewed and highly commended by my co-authors as well as one of the world leaders in the posttranscriptional regulation of gene expression field, Dr. Jack Keene from Duke University, USA.

GIGUERE, Vincent

Editorial Boards

Molecular Endocrinology (1995-1998), (2007-2009), (2010-2012)

Grant Reviews

CCSRI Innovation Grant Panel I1b, Gene Expression, Member (2012)

Meetings

Poster Judge Competition, 94th Annual Meeting of the Endocrine Society, Houston, TX, USA, June 2012.

Invited Speaker

March 2012. Invited speaker, Educational Sessions on “Nuclear Receptors as Therapeutic Targets in Cancer, American Association for Cancer Research Annual Meeting, Chicago, Illinois, USA.

April 2012. Invited speaker*, Keystone Symposia on Nuclear Receptors, Whistler, BC, Canada.*Talk given by Lillian Eichner.

May 2012. Invited speaker, La Cité de la Biotech 10th Anniversary Symposium, Montréal, QC, Canada.

June 2012. Invited speaker, Annual Meeting of the Endocrine Society, Symposium on “Nuclear Receptors and Metabolic Diseases”, Houston, Texas, USA.

GROS, Philippe

Grant Reviews

CIHR, Panel Member, Knowledge Diffusion Grant Committee (2011-present)

Canadian Gene Cure Foundation, Panel Member, Champions of Genetics Program (2010-on)

Burroughs-Wellcome Fund, Advisory Committee, “Investigators in Infectious Diseases Program” (2003-Present)

Governance

Canadian Institutes for Health Research, *Knowledge Diffusion Panel (2010-)*

McLaughlin-Rotman Center for Global Health, University Health Network, University of Toronto, Member, External Advisory Board (2004- Present)

Canadian Genetic Diseases Network (CGDN), Scientific Director (2005- 2007)

Canadian Gene Cure Foundation, Scientific Director (2007-Present)

Bill and Melinda Gates Foundation, Grand Challenges Explorations Program (Evaluation Panel)

Goodman Cancer Research Centre Annual Report 2012

Patents

“Inflammation-enabling polypeptides and uses thereof cross-reference to related applications” Gros, P.; US Provisional Patent Application serial No. 61/652,271; Filed May 25th 2012.

Internal Committees

Search committee for recruitment into the Life Sciences Complex, McGill University, Faculty of Medicine

Planning Committee, Strategic Research Plan, McGill University, Faculty of Medicine

Management Committee, Transgenic Core Facility, McGill University, Goodman Cancer Research Centre

Invited Speaker, Scientific Meetings

ASM Biodefenses and Emerging Diseases Research Meeting, Washington, DC, USA; February 26-29, 2012; “Host Genetic Resistance to Mycobacterial Infections: The Case of *Mycobacterium tuberculosis*”

New Perspective in Immunity and Infection, Heidelberg, Germany; May 19-22, 2012 “Role of IRF transcriptional regulators in response to infection and in acute inflammation”.

Infectious Diseases Society of America; “Advancing science, improving care” San Diego, CA, USA; October 17-21, 2012. “Susceptibility to Mycobacterial Infections: IRF8 and Beyond”.

Annual Symposium on Primary Immunodeficiency Diseases, Newport Beach, CA, USA; November 3-4, 2012. “Human dendritic cell immunodeficiency”

Invited Speaker, Institutions

Genome Quebec, and McGill University Innovation Center annual retreat, Montreal, QC Januray 27, 2012 (Dr. M. Lathrop). Genetic effects in susceptibility to intracellular pathogens: Genome-wide screen in ENU-mutagenized mice.

Annual Canadian Genetics and Statistical Genetics Conference, Niagara, ON, April 30, 2012. Genetic Effects in Infectious Diseases: from Mouse to Human.

Cancer and Development Graduate Research Symposium, St.John, NF. June 15, 2012. Genetic analysis of carcinogen-induced colorectal cancer in mice.

The crossroad for Biotransfer. Montreal, QC. May 29, 2012. Novel targets and Platform the anti-inflammatory drug discovery.

Dafra BVBA Pharma. Tunrhout, Belgium. May 17, 2012. Novel cysteamine-artemisinin combination for the treatment of blood-stage malaria.

UCLA, Dept. Physiology (Dr. R. Kaback) Ocotber 17, 2012. “Genetic control of susceptibility to infections: from moouse to man”.

Montreal Symposium on Novel Therapeutic Avenues in Tuberculosis, Montreal, QC, October 30, 2012. “IRF8 deficiency and susceptibility to infection with mycobacteria”.

HALLETT, Michael

Grant reviews

Canadian Institute of Health Research (CIHR) Genomics (2005-2006, 2008-2009, 2009-2010, 2012)

Conference committees

Canadian Institute of Health Research (CIHR) Genomics, Ottawa, 2012 (now Chair)

Canadian Partnership Against Cancer, Toronto, 2012

Goodman Cancer Research Centre Annual Report 2012

Canadian Institute of Health Research (CIHR) Priority Review Committee, September 2012
Canadian Cancer Research Conference – Scientific Program Committee, November 2012

Meeting organization

I am the principle organizer of an annual workshop at the McGill Bellairs Research Centre in Barbados (<http://www.mcb.mcgill.ca/research/comblab/barbados>). Each year I choose a co-organizer who is an expert in the field and invite between 15 and 20 international researchers. *11th Meeting 2012 - Deciphering the Syntax of Gene Regulation* T Hughes, University of Toronto

Invited speaker

2012 Radiation Hospital, Oslo, Norway (April 2012) *The Illusion of Accuracy in Breast Cancer Prognosis*

JONES, Russell

Director, McGill University Flow Cytometry Core Facility, 2009 – present

Meetings organized

Co-organizer, FASEB Summer Research Conference: AMPK and Beyond: Biology, Disease Mechanisms and Therapeutic Opportunities, Asilomar, CA, USA, October 7-12, 2012

Grant reviews

Member, Cancer Research Society (CRS) review panel, 2012

Member, CIHR grant panel: Cancer Biology and Therapeutics, 2009 – present

Internal Committees

Member, Defi Canderel Studentship and Fellowship Grant Committee, Goodman Cancer Research Centre, McGill University, 2008 – 2012

Member, Faculty of Medicine Studentship and Fellowship Grant Committee, McGill University, 2008 – 2012

Member, Downtown FACC (Animal Care Committee), McGill University, 2008 – 2012

Ad Hoc Reviewer for Journals

Nature, Immunity, Cell Metabolism, Oncogene, Cancer Research, Journal of Immunology, European Journal of Immunology, Science Signaling, PLoS One

McCAFFREY, Luke

Journal Reviews

2009 – 2012 Journal of Cell Biology (reviewed 3 manuscripts)

2009-present Faculty of 1000

2011 – 2012 Molecular Cell (reviewed 1 manuscript)

Grant Panels

2011-2013 Reviewer, Panel C, Cancer Research Society

2012-2013 Reviewer, Panel A, Canadian Breast Cancer Foundation – Ontario Region

Goodman Cancer Research Centre Annual Report 2012

Internal Committees

- 2010-Pres. Member, McGill Integrated Cancer Research Training Program Committee
- 2011-Pres. Chair, Canderel Committee
- 2011-Pres. Member, Histology Core Committee
- 2012-Pres. Member, GCRC Training Committee

Invited speaker

- 2012 "Disrupted Par3/aPKC Polarity Signaling Promotes Breast Tumourigenesis and Metastasis" Terry Fox Research Institute Annual Scientific Meeting, Victoria, BC.
- 2012 "Challenges in Collaborative Research: A New Investigator's Perspective". Terry Fox Research Institute Annual Scientific Meeting, Victoria, BC.

MULLER, William

Grant Panels

- 2000-present Member, Scientific NIH PPG Advisory Panel, UCSF
- 2001-present Member, Scientific NIH PPG Advisory Panel, Ohio State
- 2002-present Member, Scientific NIH Advisory Panel, Albert Einstein School of Medicine
- 2005-present Member, US Army Integration Panel
- 2010-present Chair of CRS Panel D

Ad hoc Journal Reviews

Molecular and Cellular Biology, Science, Nature, Cancer Cell, PNAS, Cancer Letters, Oncogene, Nature Medicine, Nature Structural Biology, Genes and Development, Journal of Cell Biology, Cancer Research, Molecular and Cellular Biology

Invited Speaker

- Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. Think Tank 22, Cancun, Mexico, Jan 15-21, 2012.
- Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. Burnham Institute Jan 30, 2012.
- Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. Think Tank 22, Cancun, Mexico, Jan 15-21, 2012.
- Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. University of Manitoba, March 7, 2012.
- Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. IABCR, Manchester, UK, April 15-18, 2012.
- Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer, Terry Fox Frontiers, Victoria, BC, May 10-12, 2012.
- Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. FASEB , Aspen, Co, July 22-27, 2012.
- Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. OSHU, Portland, Oregon, August 6-8, 2012.
- Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. NIH MMHC, UPenn, Philadelphia, Nov. 29-30, 2012.

Goodman Cancer Research Centre Annual Report 2012

NEPVEU, Alain

Editorial Board

Editor, Gene, 2011-present

Grant reviews

CRS 2012, Tumour Suppressor Genes, Oncogenes and DNA Repair

Studentship and Fellowship Review Panels

McGill University Health Center Research Institute, Studentships and Fellowships, 2007-2012

McGill Integrated Cancer Research Training Program, 2010-2012

Fonds de recherche Nature et technologies, B1, Biologie moléculaire, 2011, 2012

Public Awareness

"Relais pour la vie de Gatineau 2012", at the Centre Asticou, 241, Boulevard de la Cité-des- Jeunes, Gatineau, Québec. On this occasion, I gave a seminar to the survivors and their families.

Internal Committees

Recruitment Committee, Goodman Cancer Center, Chairman, 2008-2012

Promotion Committee, Department of Oncology, 2011- present

Space and Equipment Committee, Goodman Cancer Centre, Chairman, 2012-present

Invited speaker

Aug 2012 Guest of the students, Journée scientifique des étudiants, Hôtel-Dieu de Québec

Aug 2012 Gordon Research Conference on Mutagenesis, Salve Regina University, Newport,

June 2012 Centre du Cancer Paul Papin, Angers, France

June 2012 Université de Lyons, France

May 2012 First Canadian Symposium on Telomeres & Genome Integrity

Feb 2012 Workshop on Bioinformatics in Transcription, Belairs Research Station, Barbados.

PARK, Morag

Professional and Scientific Contributions

Member, Gairdner Foundation Medical Review Panel, 2011-2014

Member, Cancer Stem Cell Consortium (CSCC), 2008-present

Member, WHO-International Agency for Cancer Research (IARC), Governing Council, Lyon, France, 2008-present

Site Visits and Advisory Panels

2012 Arizona Cancer Centre, Strategic Review

Internal Committees

Faculty of Medicine Search Committee, Member for Chair of Oncology

Steering Committee for Strategic, Member, Research Priorities, Faculty of Medicine

Gerald Bronfmann Centre Merit Awards, Member

Goodman Cancer Centre, Finance Committee, Chair, 2009-present

Goodman Cancer Research Centre Annual Report 2012

Invited speaker, International

- Dec 2012 Invited speaker, CTBC-AACR, San Antonio Breast Cancer Symposium, San Antonio, Texas, USA
- Nov 2012 Invited speaker, 43rd International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan
- Oct 2012 Invited speaker, Ohio State University, Ohio, USA
- Aug 2012 Invited speaker, Salk Post Translational Regulation of Cell Signaling, Salk Institute, La Jolla, California, USA
- July 2012 Invited speaker, FASEB Science Research Conference, Snowmass Village, Colorado, USA
- Jun 2012 Invited speaker, COST Conference, “Personalized Medicine: Better Healthcare for the Future”, Larnaca, Cyprus
- Apr 2012 Invited speaker, Annual American Association for Cancer Research Meeting, Chicago Illinois, USA
- Mar 2012 Invited speaker, MCB/CMM Department Seminar, The University of Arizona Cancer Center, Tucson, Arizona, USA

Invited speaker, National

- Nov 2012 2nd Annual Gerald Bronfman Centre Symposium and Awards Ceremony, Montreal Neurological Institute and Hospital, Montreal, QC, Canada
- Feb 2012 Invited speaker, BC Cancer Agency Research Seminar, Vancouver, BC
- Feb 2012 Invited speaker, Science Talks about Research for Staff (STARS) Lecture Series, McGill University, Montreal, QC, Canada
- Feb 2012 Invited speaker, Ontario Institute of Cancer Research and McMaster University, Toronto and Hamilton, ON, Canada

PAUSE, Arnim

Grant Panels

- 2012 Peer reviewer of Medical Research Council (UK) Operating grant
- 2012-present Member of Operating Grant Panel of Romanian National Council for Scientific Research
- 2012-present Member in Defi Canderel Defi Canderel Studentship and Fellowship Grant Committee, McGill Cancer Center MUHC, Oncology, and other biomedical departments.
- 2010-present Member in Operating Grant Panel of the Kidney Foundation of Canada
- 2009-present Member of Research Award Committee of von Hippel-Lindau Family Alliance
- 2008-present Member of the Research Award Committee of the Canadian Liver Foundation
- 2005-present Member of the College of Reviewers for CRC chairs
- 2007-present Reviewer for the Saskatchewan Health Research Foundation
- 2005-present Mentor and Member of the Canadian National Hepatitis C Research Training Program (NCRTP-HepC).

Conference organizing

- 2012 Invited speaker, Member of the Scientific Committee, and Session Chair: The Fourth Birt-Hogg-Dube (BHD) Symposium, Cincinnati, USA.

Goodman Cancer Research Centre Annual Report 2012

Internal Committees

- 2012-present Member of Education Committee of the Goodman Cancer Research Centre
- 2012-present Coordinator of the Website of the Goodman Cancer Research Centre
- 2011-present Committee for hiring of a PI for Cancer Metabolism in the Goodman Cancer Research Centre
- 2012-present Committee for hiring a senior administrator and a senior scientific administrator and fundraiser for the Goodman Cancer Research Centre

Scientific Advisory Boards

- 2012-present Member of SAB Myrovlytis Trust, UK.
- 2010-present Member of SAB for Proreio Pharma Innovation AG, Basel, Switzerland.
- 2006-present Consultant for Insymbiosis Discovery, Inc. Montreal, Canada.

Invited speaker

- 2012 Speaker at the FASEB meeting on: “AMPK and Beyond: Biology, Disease Mechanisms and Therapeutic Opportunities”. Pacific Grove, California
- 2012 Invited speaker, Member of the Scientific Committee, and Session Chair: The Fourth Birt-Hogg-Dube (BHD) Symposium, Cincinnati, USA.
- 2012 Invited Speaker at VHL Medical Symposium, MD Anderson Cancer Center, Houston, TX, USA.

PELLETIER, Jerry

Patents

PCT/US 61,612,426. Altering survival dependencies in cells and uses thereof. Mills, J., Malina, A., and Pelletier, J. (Filed Jan. 3, 2012).

Grant reviews

Member FRSQ Grant Review Panel for Chercheurs Boursiers Senior (Volet Fondamental), Feb. 2-3. 2012.

Internal Committees

Scientific Co-Director of the McGill University High Throughput Chemical Screening Facility (2002-Present). (see <http://www.medicine.mcgill.ca/biochem/htsfacility/>).

Biochemistry GAC Committee Member (2010-Present).

Member of Chemical Biology Studentship Evaluation Panel (2003-Present). In 2012, we meet June 6th, Dec 11th, and Dec 12th.

Invited speaker

Pelletier, J. (2012). ImClone – New York. Targeting Translational Control for Therapy. Oct. 1st.

SHORE, Gordon

Invited speaker

8th International Barbados Workshop: From Molecular Cell Biology to Clinical Proteomics, Folkestone, Feb 21, 2012

Goodman Cancer Research Centre Annual Report 2012

SIEGEL, Peter

Grant reviews

2012 CBCF/CIHR – Breast Cancer in Young Women, CBCF/CIHR – Workshop
2012, 2013 Research Grant Competition, CRS (Panel C2, Chair)
2012, 2013 Research Grant Competition – Impact, CCSRI

Internal Committees

Goodman Cancer Research Centre

Interim Director, 03/2012-06/2013

Oversee the general operation of the GCRC, conduct evaluations of faculty, oversee administrative (15) and research (12) staff, and serve as chair/member of several committees within the Centre (9 active committees).

Strategic Planning Committee, 2012-present

Finance Committee, 2011-present

Equipment and Space Committee, 2010-present

Recruitment Committee, 2012-present

Histology Core Committee, 2009-present

Faculty of Medicine

Faculty Leadership Council, 2012 – present

Bellini Search Advisory Committee, 2012 – present

Oncology Management Committee, 2012 – present

Search Committee – MNH (Neurosurgeon recruit), 2012 – 2013

Search Committee – Herbert Black Chair (Surgical Oncology), 2012 – 2013

Invited speaker

(2012, Feb.) Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, Canada

(2012, Apr.) BONUS7 (Breast Cancer and Bone Disease Updates), National Arts Centre (Ottawa), Ottawa, Canada

(2012, June) Cancer Seminar Series, Lady Davis Institute, McGill University, Montreal, Quebec

(2012, June) Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York

SONENBERG, Nahum

Committee Memberships/Editorship

2008-present External Advisory Board – MRCE (Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research)

2010-present Editorial Board, WIRES RNA

2011-present Editorial Board, Current Opinions in Cell Biology

Editor

N. Sonenberg, M.B. Mathews and J.W.B. Hershey, eds (2012). Perspectives in Biology: Translational Control. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

Goodman Cancer Research Centre Annual Report 2012

Meetings Organized

2012 EMBO/EMBL Symposium 2012 “Complex Life of mRNA”. October 7-10, 2012. EMBL, Heidelberg, Germany. Co-organizer with D. Tollervy, J. Steitz and A. Ephrussi.

Invited Presentations

Cold Spring Harbor Laboratory. 2012 meeting on “PTEN Pathways & Targets”. March 13-17, 2012. Cold Spring Harbor Laboratory, N.Y. “Downstream of mTOR”.

Brandeis University March 29, 2012. Waltham, MA. Lewis S. Rosenstiel Award Lecture “Translational control of cancer, learning and memory”.

AACR 103rd Annual Meeting 2012. Chicago, IL. March 31-April 4, 2012. “Translational control of cancer”

ASBMB 2012 Annual Meeting. San Diego, CA. April 21-25, 2012. “Mechanism of action of miRNA”. Regulation of Protein Translation Symposium, Stanford University School of Medicine. Stanford, CA. May 17-19, 2012. “Translational control of cancer”.

“mRNA fate workshop” Life and Death of mRNA in the Cytoplasm. Riva del Garda, Italy. May 23-26, 2012. *Invited Speaker-Keynote Lecture and Session Chair*.

Symposium on RNA pathobiology in cancer. Medical University of South Carolina, Charleston, SC. June 7th, 2012. *Invited Session Chair and Speaker*. “Translational control of cancer”.

2012 FASEB Summer Research Conference: “Post-transcriptional Control of Gene Expression: Mechanisms of mRNA Decay”. Steamboat Springs, Co. June 24-29, 2012. “Mechanism of miRNA action”.

27th Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy. Aspen, CO. July 14-17, 2012. “Translational control of cancer”.

Cold Spring Harbor Laboratory. 2012 meeting on “Translational Control”. Cold Spring Harbor, NY. September 4-8, 2012. *Session Chair*: “Translation and Cancer” and *Invited Speaker*.

EMBO/EMBL Symposium: “The Complex Life of mRNA”. Heidelberg, DE. October 7-10, 2012. Co-organizer with D. Tollervy, J. Steitz and A. Ephrussi. “Structural insights into miRISC recruitment of the CCR4-NOT complex”.

The Stowers Institute for Medical Research. Kansas City, MO. November 28, 2012. “Translational control of cancer and autism”.

ST-PIERRE, Julie

Editorial Board

Médecine Sciences Amérique (MSA) Journal, 2012-present

Grant Panels

Cancer Research Society, Panel D: tumor progression and metastasis, ~40 hours of grant review and 2 days meeting per year, 2010-2012

Fonds de la Recherche en Santé du Québec, Comité des bourses de formation postdoctorale, ~40 hours of application review and 2 days meeting per year, 2011-2013

Canadian Institutes of Health Research, Panel Cancer Progression & Therapeutics, ~40 hours of grant review and 2 days meeting per year, Fall 2011, Fall 2012, Spring 2013

University Administration

Scientific Director of the metabolomics platform, Goodman Cancer Research Centre, 01/2010-present.

McGill Representative, Co-trustee for the charitable trust (Michael D’Avirro succession) that was given to the Goodman Cancer Research Centre, 2009-present

Goodman Cancer Research Centre Annual Report 2012

Internal Committees

Academic Committee for McGill University, Member, ~18 hours/year, 2010-present
Postgraduate Awards Committee, Faculty of Medicine, Reviewer, 25 hours/year, 01/2011-12/2014
Junior Seminar Evaluation Committee, Department of Biochemistry, McGill University, Examiner, ~10 hours/year, 09/2008-present
Teaching Committee, Department of Biochemistry, McGill University, Member, ~3 hours/year, 2012-present
Recruitment Committee, Goodman Cancer Research Centre, Member, ~10 hours/year, 2011-present
Equipment and Space Committee, Goodman Cancer Research Centre, Member, ~5 hours/year, 2012 present

Evaluator for Poster Session at Conference

Signalisation Québec Conference, Bécancour, Canada, June 13-15, 2012

Invited speaker

PGC-1alpha at the crossroads of metabolism and cancer. 'Chewing the Fat' symposium in Honor of Dr. Bruce Spiegelman. Harvard Medical School, Boston, USA, November 2, 2012.
Metabolic regulation by the PGC-1 transcriptional coactivators. Research Awareness Day, Department of Biochemistry, McGill University, Montréal, Canada, September 22, 2012.
Impact de PGC-1alpha sur le métabolisme et la prolifération des cellules cancéreuses du sein. Signalisation Québec 2012, Bécancour, Canada, June 13-15, 2012.

TEODORO, Jose

Editorial Board, Oncology Letters, 2009-present

Grant Panels

Cancer Research Society, 2008-2010, Panel C: Tumor suppressor genes, Oncogenes and DNA Repair. Returned to panel in 2012. 2 meeting days/year.
CIHR Molecular and Cellular Biology of Cancer (MCC), panel member, 2010-present
Fonds de la recherche en santé (FRSQ) Junior 1 Salary Awards 2010-present

Meetings organized

Organizer of the 2012 International DNA Tumour Virus Meeting

Ad hoc Journal reviews

Current Pharmaceutical Design, Apr 2012.
Trends in Microbiology, Apr 2012.

Internal Committees

Goodman Cancer Centre Safety Committee, Chair, April 2007-present
Goodman Cancer Centre Finance Committee, 2011-present
Goodman Cancer Centre Research and Space Management Committee, 2008-present
Coordinator of the Goodman Cancer Research Centre Seminar Series, 2009-present
Goodman Cancer Centre Space and Equipment Committee, 2012-present. 10 hours/year
McGill Biochemistry Undergraduates Student Society (BUGS) Poster Day, Poster Judge, Jan 24, 2012

Goodman Cancer Research Centre Annual Report 2012

Invited Speaker

McGill University, Department of Microbiology and Immunology, Montreal, Quebec, Topic: Induction of Tumour-Specific Cell Death by Viral Targeting of the Anaphase-Promoting Complex. April 2012. (Invited by Dr Joaquin Madrenas)

TREMBLAY, Michel

Grant panels

At my return to Montreal in late September I had accepted to serve on the CIHR Operating grant panel: grant panel MCC panel held in the fall 2012.

Journal Reviews

During the sabbatical I maintain all my duties of ad-hoc reviewers including in the following journals and more: J. Biol. Chemistry, European Journal of Immunology, FEBS, CHEM BIOCHEM, Journal of Cell Biology, Blood, J. of Exp. Medicine, Cell Metabolism

Community Outreach

Speaker at the Goodman cancer centre public evening lecture on prostate cancer.

Internal Committees

I served as reviewer for the VP-Research internal grants.
I serve on the Recruitment committee St-Mary's chair in breast cancer.
Award committee of the Faculty of Medicine

External Committees

I maintained the following appointments and contributed by conference call as:
Secretary, International Society of Pathophysiology
Member of the Advisory Committee On Research, Canadian Cancer Society
Member of the advisory committee: International Consortium on Mouse Genetics
Member of the "Table de travail sur la recherche", Montreal In Vivo.

Invited speaker

Phosphatases in diseases. Monash University, Australia 2012
Aichi Cancer Center Research Institute, Nagoya Japan. March 30th, 2012
Tyrosine phosphatases in human diseases, Kobe University Medical School, Japan. June 1, 2012.
The Protein Tyrosine Phosphatases. Meeting Keynote lecturer. Signaling Quebec, Becancour Quebec, Canada. June 14, 2012
Congres annuel du Club de Recherche Clinique Du Quebec. Conferencier invite gagnant du Prix Michel Sarrazin. Octobre 10, 2012
University of North Carolina. Dept of cardiology, Dec. 3 2012 PTP1B in cardiovascular and metabolic diseases
Tyrosine phosphatases in the normal and disease brain. Dept of Neurosciences, University of Ottawa November 26, 2012
University of North Carolina. Dept of cardiology, Dec. 3 2012 PTP1B in cardiovascular and metabolic diseases

YAMANAKA, Yojiro

Grant reviews

2011, 2012, Czech Science Foundation (as an external expert)

Journal Reviews

Reproduction (2012-Oct, 2010-Nov, Dec)

Molecular Human Reproduction (2012-Feb, 2011-Jan, 2010-Jun)

Developmental Dynamics (2012-Feb, 2008, 2009)

PLOS one (2012-Nov)

Meetings organized

Nov.7 2012, 2nd MAD symposium, organizer

Internal Service/Committees

2012 Sep- Interim manager of the GCRC transgenic facility

2011 Jan- 2013 Dec A member of the Postgraduate Awards Committee of the Faculty of Medicine

2010 Apr- Director of the GCC transgenic facility

Invited speaker

2012 Apr. Montreal Children's Hospital, Canada

YANG, Xiang-Jiao

Journals

Editorial Board Member, Genes & Cancer, 2009-present

Advisory Board Member, Biochem. J., 2010-present

PeerJ (an online journal to be launched by a founder of *PLOS One*), 07/2012-present

Grant Panels

CIHR Postdoctoral Fellowship Review Committee Member, 2011-present

Internal Committees

Goodman Cancer Center, recruitment committee member, 2007-present

Goodman Cancer Center, Space & equipment committee member, 2012-present

MUHC (McGill University Health Center) Research Institute, 2003-present. Two competitions/year; reviewing ~35 applications per competition (~10 hrs/yr)

Ad hoc grant reviews

NSERC

Israel Science Foundation (ISF)

Research Grants Council, Hong Kong

National Science Council, Taiwan

ZANNIS-HADJOPOULOS, Maria

Editorial Board

1997 Member, Editorial Board, International Society for Gene Therapy & Molecular Biology

Internal Committees

1984-present Member, Royal Victoria Hospital Ethics

1993-present Medical Education Committee, Dept. of Oncology

1999-present Coordinator, Oncology Graduate Program (Stream)

2000-2014 Elected Member (every 2 years), McGill Association of University Teachers MAUT) Council

2004-present Member, McGill Centraide Campaign Committee (MAUT Representative)

2006-present Member, Biochemistry Departmental Tenure Committee

2006-present Member, Biochemistry Department Recruiting Committee

2010-2013 Assessor for McGill University (nominated), Harassment, Sexual Harassment and Discrimination Prohibited by Law

External Committees

1997-present Member, Organizing Committee/Scientific Advisory Board of the Annual Conferences, International Society for Gene Therapy and Molecular Biology

1999-present Member, Scientific Advisory Board, Replicor

2003-present External Reviewer, European Science Foundation//EUROCORES

2004-present Member, Academic Committee, Hellenic Scholarships Foundation

2005-present Evaluator of grant applications submitted to the Greek Ministry of Research and Technology (PENED)

2008-present Member, Hellenic Quality Assurance Agency For Higher Education (H.Q.A.A.), evaluations of Departments in the field of Life Sciences.

2009-present Member, Mispro Biotech Animal Care Committee

Ongoing

Member, Dept. of Biochemistry Hiring Committee

Member, Goodman Cancer Centre Recruiting Committee

Pro-Dean, McGill Graduate and Postdoctoral Studies

Member, Ph.D. Thesis Defense Committees, External and Internal examiner, M.Sc. and Ph.D. Theses

Invited speaker

Department of Pathology and Anatomy, University of Athens, May 25, 2012

ZOGOPOULOS, George

Internal Committees

2013-present Member, Training Committee, Rosalind and Morris Goodman Cancer Research Centre

2012 Reviewer, Studentship and Fellowship Competition, McGill Integrated Cancer Research Training Program

2012 Reviewer, Studentship and Fellowship Competition, the Research Institute of the McGill University Health Centre.

Goodman Cancer Research Centre Annual Report 2012

External Committees

2011-present Member, Research Committee, *American Hepato-Pancreato-Biliary Association*.

2012 Reviewer, Abstract Submissions, 2012 Meeting of the *International Hepato-Pancreato-Biliary Association*.

Invited Speaker

Quebec Pancreas Cancer Study, Cancer Axis Research Day, the Research Institute of the McGill University Health Centre, Montreal, Quebec, 2012.

Le Whipple dans l'adénocarcinome du pancreas, 43^e congress, L'Association québécoise de chirurgie, Quebec City, Quebec, May 2012.